APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/699,035	10/31/2003	John Francis Bateman	A36056-PCT-USA-A	3842

21003   7590   03/31/2006

BAKER & BOTTS
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112

EXAMINER
HADDAD, MAHER M

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 03/31/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.
- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on <u>25 January 2006</u>.

2a)☐ This action is **FINAL**.   2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) <u>1,2,4,5,7,8,11 and 12</u> is/are pending in the application.

    4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) <u>1-2, 4-5, 7-8 and 11-12</u> is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

    Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

    Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

    a)☐ All   b)☐ Some * c)☒ None of:

      1.☐ Certified copies of the priority documents have been received.

      2.☐ Certified copies of the priority documents have been received in Application No. _____.

      3.☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

    * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.

4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

5) ☐ Notice of Informal Patent Application (PTO-152)

6) ☒ Other: *Sequence alignment*.

DETAILED ACTION

1. Claims 1-2, 4-5, 7-8 and 11-12 are pending.

2. Applicant's election of Group I, claims 1-14 (now 1-2, 4-5, 7-8 and 11-12) drawn to an isolated polypeptide, derivative or homolog thereof of WARP and a polypeptide of human WARP of SEQ ID NO: 6 encoded by SEQ ID NO:5 and the VA domain of SEQ ID NO:2 encoded by SEQ ID NO: 1 as the species filed on 1/25/06, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

3. Claims 1-2, 4-5, 7-8 and 11-12 are under examination as they read on an isolated polypeptide, derivative or homolog thereof of WARP and a polypeptide of human WARP of SEQ ID NO: 6 encoded by SEQ ID NO:5 and the VA domain of SEQ ID NO:2 encoded by SEQ ID NO: 1 as the species.

4. There does not appear to be a shared common structural relationship between the nucleotide of SEQ ID NO: 5 and the polypeptide of SEQ ID NO:6. SEQ ID NO:5 is missing a codon corresponding for Asp amino acid of SEQ ID NO: 6 at position 211.

5. The references cited in the Search Report PCT/AU02/00542 have been considered, but will not be listed on any patent resulting from this application because they were not provided on a separate list in compliance with 37 CFR 1.98(a)(1). In order to have the references printed on such resulting patent, a separate listing, preferably on a PTO/SB/08A and 08B form, must be filed within the set period for reply to this Office action.

6. Applicant's IDS, filed 10/4/04, is acknowledged, but will not be listed on any patent resulting from this application because they were not provided on a separate list in compliance with 37 CFR 1.98(a)(1). In order to have the references printed on such resulting patent, a separate listing, preferably on a PTO/SB/08A and 08B form, must be filed within the set period for reply to this Office action.

7. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Page 10, lines 2, 8, and 20, and page 53, ¶143 contain embedded hyperlinks and/or other forms of browser-executable code which are impermissible and require deletion.

8. The specification is objected to for the following informalities: The SUMMARY OF SEQUENCE IDENTIFIERS on pages 12-14, discloses several sequences, however, it is not

clear as what is the structural difference between SEQ ID NO: 6 and SEQ ID NO: 20. Further, in title of Example 11, the letter "f" should be "of". Correction is required.

9. The specification is objected to under 37 CFR 1.821(d) for failing to provide a sequence identifier for each individual sequence. Figure 1A, Figure 1C, Figure 2A, and Figure 2B on pages 9-10 have described several sequences that each must have a sequence identifier. Correction is required.

10. Acknowledgment is made of a claim for foreign priority under 35 U.S.C 119(a)-(d) for Australia PR4701, however no copies of the certified copies of the priority documents have been received in this National Stage application from the international Bureau. A courtesy copy is required.

11. Claims 7 and 11 are objected to because "a set forth" should be "as set forth". Correction is required.

12. The following is a quotation of the second paragraph of 35 U.S.C. 112.
> *The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.*

13. Claims 1, 4, 7 and 11-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

    A. The recitation "substantially" in claims 1, 4, 7 and 11 are indefinite and ambiguous. The metes and bounds the term is not clear.

    B. Claims 11-12 are indefinite. Claims 11-12 depend from claim 1, claim 1 recites a polypetide encoded by a nucleotide sequence having at least 65% similarity to SEQ ID NO:1, which is a fragment, however, claims 11-12 recite the fullength polypetide which fail to further limit the polypeptide.

14. 35 U.S.C. § 101 reads as follows:
"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title".

15. Claims 1-2, 4-5, 7-8 and 11-12 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and/or substantial asserted utility or a well established utility.

Applicant is directed to the Utility Examination Guidelines, Federal Register, Vol. 66, No. 4, pages 1092-1099, Friday January 5, 2001.

The instant application has provided a description of a nucleotide encoding a polypeptide and an antibody against the polypeptide. The instant application does not disclose the biological role of

the claimed polypeptide or its significance. The instant specification asserts specific utilities for the claimed invention as a molecular marker of the integrity of the extracellular matrix in an animal including a human subject. In particularly, the specification also asserts that thee polypeptide of the invention provides a molecular marker of cartilage integrity. Further, the specification asserts that the identification of the molecular marker in circulating or tissue fluid is indicative of disrepair of the extracellular matrix and in particular cartilage such as caused or facilitated by trauma or a degenerative disease or other condition , for example, arthritis or autoimmunity (see page 1, 1¶). In Addition the specification assets that the identification of the molecular marker of present invention enables the development of a range of diagnostic and therapeutic agents for degeneration of extracellular matrix or the poor development of the matrix at the fetal and postnatal stages, including testing for mutation in the gene sequence in human disease, such as, but not limited to, cartilage disease or arthritis (see page 2, 1¶). Furthermore, the specification on page 3, 4¶ discloses that the WARP protein is a member of the expanding von Willebrand factor Type A-domain (VA) protein superfamily participate in variety of functions including hemostasis, cell adhesion and protein-protein interactions between matrix molecules.

These utilities are not considered to be specific and substantial because the specification fails to disclose any particular function or biological significance for von Willebrand A-Related protein "WARP". The disclosed polypeptide is said to have a potential function based upon its amino acid sequence similarity (unspecified) to other known proteins comprising VA-domain such as FACIT collagen XII, XIV and the recently described FACIT collagen XX and XXI, the Matrilins and Cochlin. A-domains are thought to mediate interactions with other proteins via the metal ion dependant adhesion site (MIDAS) motif and their involvement in oligomerisation, filamentous network formation, and cell adhesion and spreading has been reported (see Example 11). After further research, specific and substantial credible utility might be found for the claimed isolated compositions. However, the specification on page 4, 5¶ discloses that the VA module is an independently folding protein unit that attains a classic $\alpha\beta$ "Rossman" fold consisting of a parallel β sheet surrounded by amphipathic a helices, and in the majority of VA domains, a metal ion-dependent adhesion site (MIDAS) at the C-termianl end of the β sheet. This suggests that this domain originally evolved from a Rossmann fold acquiring specialized functions, apparently related to multiprotein assemblies and perhaps involving divalent cations.

This further characterization, however, is part of the act of invention and until it has been undertaken, Applicant's claimed invention is incomplete. While the specification on page 58 under Example 14 discloses that WARP is an oligomeric protein expressed in cartilage matrix, however, WARP also exists in a number of pools of differing solubilities and possibly different functions during development or maturation. However, since the specification fails to demonstrate "a differential expression" in both normal and a degenerative disease, methods of identifying or therapeutic regiments is not substantiated. The presence of WRAP in chondrocyte cells which is secreted to the cartilage matrix is not sufficient for establishing a utility in diagnosis of a disease in the absence of some information regarding a correlative or causal relationship between the expression of the polypeptide, and the disease. While a number of

diseases arise from mutations in VWA domains, the specification fails to identify any disease for comparative study, particularly those with WARP defects, to allow any in depth correlations to be derived.

The instant situation is directly analogous to that which was addressed in *Brenner V. Manson*, 148 U.S. P. Q. 689 (1966), in which a novel compound which was structurally analogous to other compounds which were known to possess anti-tumor activity was alleged to be potentially useful as an anti-tumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 U.S. C. § 101, which requires that an invention must have either an immediately apparent or fully disclosed "real world" utility. The instant claims are drawn to a polypeptide of as yet undetermined function or biological significance. There is no evidence of record or any line of reasoning that would support a conclusion that the WARP of the instant application was, as of the filling date, involve in variety of functions including hemostasis, cell adhesion and protein-protein interactions between matrix molecules. Until some actual and specific significance can be attributed to the protein identified in the specification as WARP, one of ordinary skill in the art would be required to perform additional experimentation in order to determine how to use the claimed invention. Thus, there was no immediately apparent or "real world" utility as of the filing date.

No single effect of the disclosed WARP is ascribed to the claimed protein. Note that while the specification produces the full-length protein recombinantly, no biological activity is established for the full length protein or any of the claimed derivative or homolog thereof. As such, further research would be required to identify or research such as studying the properties of the claimed product itself or the mechanisms in which the material is involved would be required. Since the instant specification does not disclose a credible "real world" use for WARP, then the claimed invention as disclosed does not meet the requirements of 35 U.S. C. § 101 as being useful.

The proteins of the instant invention are compounds, which share some structural similarity with ECM proteins based on sequence similarity. It is not clear if the protein of the instant application would have the same function in variety of functions including hemostasis, cell adhesion and protein-protein interactions between matrix molecules. Attwood (Science 2000; 290:471-473) teaches that "[i]t is presumptuous to make functional assignments merely on the basis of some degree of similarity between sequences. Similarly, Skolnick et al. (Trends in Biotech. 2000; 18(1):34-39) teach that the skilled artisan is well aware that assigning functional activities for any particular protein or protein family based upon sequence homology is inaccurate, in part because of the multifunctional nature of proteins (e.g., "Abstract" and "Sequence-based approaches to function prediction", page 34). Even in situations where there is some confidence of a similar overall structure between two proteins, only experimental research can confirm the artisan's best guess as to the function of the structurally related protein (see in particular "Abstract" and Box 2). To employ the WARP protein of the instant invention in any of the disclosed methods would clearly be using it as the object of further research. Such a use has been determined by the courts to be a utility which, alone, does not support patentablility. Since the

instant specification does not disclose a "real world" use for "WARP", then the claimed invention as disclosed does not meet the requirement of 35 U.S.C. § 101 as being useful.

16. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

17. Claims 1-2, 4-5, 7-8 and 11-12 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and/or substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to used the claimed invention.

Further, besides an isolated polypeptide comprising the polypeptide of human WARP of SEQ ID NO: 6, a polypeptide encoded by SEQ ID NO:5, an isolated polypeptide consisting of the VA domain of SEQ ID NO:2 encoded by SEQ ID NO: 1, the specification fails to provide any guidance as to how to make <u>an isolated polypeptide or "any derivative or homolog thereof" which in situ forms part of the extracellular matrix (ECM) in a mammal, wherein said polypeptide "comprises" a von Willebrand Factor A (VA)-related domain encoded by a nucleotide sequence selected from the group consisting of: i) a nucleotide sequence substantially as set forth in SEQ ID NO: 1/5, ii) any nucleotide sequence "having" "at least about 65% similarity" to SEQ ID NO: 1/5; and iii) any nucleotide sequence "capable of hybridizing" to SEQ ID NO:1/5 or the complement of SEQ ID NO:1/5 under "low stringency conditions" in claims 1 and 4, wherein the nucleotide sequence is SEQ ID NO: 1/5 in claims 2 and 5, wherein the polypeptide comprising an amino acid sequence substantially as set forth in SEQ ID NO: 2, or an amino acid sequence having at least about 65% similarity to SEQ ID NO: 2/6 in claims 7/11, wherein the polpetide comprises the amino acid sequence set forth in SEQ ID NO: 2/6, in claims 8/12</u> . The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

There is insufficient guidance and direction as to how to make the claimed polypeptides or a derivative or homolog thereof, encoded by any nucleotide having at least about 65% similarity to SEQ ID NO:1/5 or capable of hybridizing to SEQ ID NO:1/5 or the complement of SEQ ID NO: 1/5 under low stringency conditions.

However, there does not appear to be sufficient guidance in the specification as filed as to how the skilled artisan would make and use the various amino acids recited in the instant claims. A person of skill in the art would not know which sequences are essential, which sequences are non-essential, and what particular sequence lengths identify essential sequences. There is insufficient guidance to direct a person of skill in the art to select particular sequences or sequence lengths as essential for use to the screening assay. Without detailed direction as to which nucleic acid sequences are essential to the function of the encoded polypeptide, a person

of skill in the art would not be able to determine without undue experimentation which of the plethora of nucleic acid sequences encompassed by the instant claims would share the ability as a molecular marker in circulatory or tissue fluid of degenerative disease, other than the nucleic acid of SEQ ID NO: 5 encoding the claimed polypeptide of SEQ ID NO:6. Further, the terms "comprising" and "having" are open-ended. They would open up the claimed molecule to include unspecified amino/nucleic acids on either or both terminal of the molecule.

The claims as written encompass a broad genus of protein with a large number of possibilities with regard to the length of the amino acid sequence. Further, making changes up to 35% of a cDNA sequence encoding the claimed protein does not provide that the encoded protein will retain the same function as the altered protein. Bork (2000, Genome Research 10:398-400) states that the error rate of functional annotations in the sequence database is considerable, making it even more difficult to infer correct function from a structural comparison of a new sequence with a sequence database (see especially p. 399). Such concerns are echoed by Doerks et al (1998, Trends in Genetics 14:248-250) who state that (1) functional information is only partially annotated in the databases, ignoring multi functionality, resulting in underpredictions of functionality of a new protein and (2) overpredictions of functionality occur because structural similarity often does not necessarily coincide with functional similarity.

The fact that two nucleic acid sequences will hybridize under low stringent conditions does not in and of itself require that the two sequences share any functional activity. Thus the same observations apply to the recitation of "nucleotide sequence capable of hybridizing" under "low stringent hybridization conditions". Further, it was well known in the art at the time the invention was made that hybridization could occur between two sequence based upon short stretches of 100% identity. Thus a great deal of sequence variability *with respect to the full-length nucleic acid* is possible. In the absence of a clear recitation that the identity is over the full length of SEQ ID NO:1/5 the claim reads on subsequences. Finally, hybridization under conditions other than high stringency would be expected to permit a great deal of variation between the two hybridizing sequences, making it even more unpredictable that the two sequences would share the same function. Thus as for the recitation of percent identity and hybridization language in the absence of *a testable function* and limitations regarding both the *hybridization conditions* and the *sequence length over which the hybridization takes place*; does not allow the skilled artisan to make and use the hybridizing nucleic acids commensurate in scope with the instant claims without undue experimentation.

Further, with respect to derivative or homolog, the specification discloses (paragraphs 49 and 50), a "derivative" includes a mutant, fragment, part, portion or hybrid molecule. A derivative generally but not exclusively carries a single or multiple amino acid substitution, addition and/or deletion. A "homolog" includes an analogous polypeptide having at least about 65% similar amino acid sequence from another animal species or from a different locus within the same species. The claims are thus rendered so broad as to be essentially useless and although directed to a WARP polypeptide, is reminiscent of *Ex parte Maizel* (27 USPQ2d 1662 at 1665)

"Appellants have not chosen to claim the DNA by what it is but, rather, by what it does, i.e.,

encoding either a protein exhibiting certain characteristics, or a biologically functional equivalent thereof. Appellants' claims might be analogized to a single means claim of the type disparaged by the Court of Customs an Patent Appeals in *In re Hyatt*, 708F.2d 712, 218 USPQ 195 (Fed. Cir. 1983). The problem with the phrase "biologically functional equivalent thereof" is that it covers any conceivable means., i.e., cell or DNA, which achieves the stated biological result while the specification discloses, at most, only a specific DNA segment known to the inventor. Clearly the disclosure is not commensurate in scope with the claims."

Reasonable correlation must exist between the scope of the claims and scope of the enablement set forth. In view on the quantity of experimentation necessary the limited working examples, the nature of the invention, the state of the prior art, the unpredictability of the art and the breadth of the claims, it would take undue trials and errors to practice the claimed invention.

18. Claims 1-2, 4-5, 7-8 and 11-12 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant is in possession of an isolated polypeptide comprising the polypeptide of human WARP of SEQ ID NO: 6, a polypeptide encoded by SEQ ID NO:5, an isolated polypeptide consisting of the VA domain of SEQ ID NO:2 encoded by SEQ ID NO: 1.

Applicant is not in possession of an isolated polypeptide or "any derivative or homolog thereof" which in situ forms part of the extracellular matrix (ECM) in a mammal, wherein said polypeptide "comprises" a von Willebrand Factor A (VA)-related domain encoded by a nucleotide sequence selected from the group consisting of: i) a nucleotide sequence substantially as set forth in SEQ ID NO: 1/5, ii) any nucleotide sequence "having" "at least about 65% similarity" to SEQ ID NO: 1/5; and iii) any nucleotide sequence "capable of hybridizing" to SEQ ID NO:1/5 or the complement of SEQ ID NO:1/5 under "low stringency conditions" in claims 1 and 4, wherein the nucleotide sequence is SEQ ID NO: 1/5 in claims 2 and 5, wherein the polypeptide comprising an amino acid sequence substantially as set forth in SEQ ID NO: 2, or an amino acid sequence having at least about 65% similarity to SEQ ID NO: 2/6 in claims 7/11, wherein the polpetide comprises the amino acid sequence set forth in SEQ ID NO: 2/6, in claims 8/12.

Neither the exemplary embodiments nor the specification's general method appears to describe structural features, in structural terms, that are common to the genus. That is, the specification provides neither a representative number of species (WARP) to describe the claimed genus, nor does it provide a description of structural features that are common to species (WARP). The specification provides no structural description of WRAP other than ones specifically exemplified; in essence, the specification simply directs those skilled in the art to go figure out for themselves what the claimed derivatives and hamologs looks like. The specification's disclosure is inadequate to describe the claimed genus of WARP polypeptides.

Applicant has disclosed only amino/nucleic acid of SEQ ID NO: 1-8; therefore, the skilled
artisan cannot envision all the contemplated polypeptide sequence possibilities recited in the
instant claims. Consequently, conception cannot be achieved until a representative description of
the structural and functional properties of the claimed invention has occurred, regardless of the
complexity or simplicity of the method. Adequate written description requires more than a mere
statement that it is part of the invention. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606
(CAFC1993). The Guidelines for the Examination of Patent Application Under the 35
U.S.C.112, ¶ 1"Written Description" Requirement make clear that the written description
requirement for a claimed genus may be satisfied through sufficient description of a
representative number of species disclosure of relevant, identifying characteristics, i.e., structure
or other physical and or chemical properties, by functional characteristics coupled with a known
or disclosed correlation between function and structure, or by a combination of such identifying
characteristics, sufficient to show the applicant was in possession of the genus (Federal Register,
Vol. 66, No. 4, pages 1099-1111, Friday January 5, 20001, see especially page 1106 3rd column).

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with
reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in
possession of the invention. The invention is, for purposes of the written description inquiry,
whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons
of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath
at page 1116.). Consequently, Applicant was not in possession of the instant claimed invention.
See University of California v. Eli Lilly and Co. 43 USPQ2d 1398.

Applicant is directed to the final Guidelines for the Examination of Patent Applications Under
the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 66, No. 4,
pages 1099-1111, Friday January 5, 2001.

19. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the
basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless --
>
> *(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in
> this country, more than one year prior to the date of application for patent in the United States.*
>
> *(e1) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the
> United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another
> filed in the United States before the invention by the applicant for patent, except that an international application filed under
> the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United
> States only if the international application designated the United States and was published under Article 21(2) of such treaty
> in the English language.*
>
> *35 U.S.C. § 102(e), as revised by the AIPA and H.R. 2215, applies to all qualifying references, except when the reference is a
> U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. For such
> patents, the prior art date is determined under 35 U.S.C. § 102(e) as it existed prior to the amendment by the AIPA (pre-
> AIPA 35 U.S.C. § 102(e)).*

20. Claims 1-2, 4, 7-8 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by WO200118022 (provided by Application).

The `022 publication teaches a polypeptide encoded by a nucleotide sequence that is 100% identical to SEEQ ID NO: 1, said nucleotide sequence would hybridize to SEQ ID NO:1 or 5 under low stringency conditions (see attached sequence alignment in particular) as claimed in claims 1-2 and 4. The `022 publication also teaches a polypeptide encoded by a nucleotide sequence having at least 99% similarity to SEQ ID NO: 5, said nucleotide would hybridize to the complement of SEQ ID NO: 5 at low stringency condition (see attached sequence alignment in particular). Further the `022 publication teaches a 215 amino acids polypeptide comprising the amino acids sequence of SEQ ID NO: 2 (see claim 11 and attached sequence alignment in particular). Further the 215 amino acids polypeptide has 99.5% similarity to SEQ ID NO:6

The reference teachings anticipate the claimed invention.

21. Claims 1-2, 4, 7-8 and 11 are rejected under 35 U.S.C. 102(e) as being anticipated by US20060003323.

The `323 publication teaches a polypeptide encoded by a nucleotide sequence that is 100% identical to SEEQ ID NO: 1, said nucleotide sequence would hybridize to SEQ ID NO:1 or 5 under low stringency conditions (see published SEQ ID NO: 2 and attached sequence alignment in particular) as claimed in claims 1-2 and 4. The `323 publication also teaches a polypeptide encoded by a nucleotide sequence having at least 93% similarity to SEQ ID NO: 5, said nucleotide would hybridize to the complement of SEQ ID NO: 5 at low stringency condition (see attached sequence alignment in particular). Further the `323 publication teaches a 445 amino acids polypeptide comprising the amino acids sequence of SEQ ID NO: 2 (see attached sequence alignment in particular). Further the 445 amino acids polypeptide has 93% similarity to SEQ ID NO:6

The reference teachings anticipate the claimed invention.

22. No claim is allowed.

23. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 7:30 am to 4:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application
Information Retrieval (PAIR) system. Status information for published applications may be
obtained from either Private PAIR or Public PAIR. Status information for unpublished
applications is available through Private PAIR only.   For more information about the PAIR
system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private
PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

March 15, 2006

Maher Haddad, Ph.D.
Patent Examiner
Technology Center 1600

```
XX
DR   WPI; 2003-111873/10.
DR   N-PSDB; AAD50397.
XX
PT   New isolated Willebrand Factor A-Related Protein polypeptide useful for
PT   the manufacture of a medicament in the treatment of a disease condition
PT   of the extracellular matrix, in particular arthritis.
XX
PS   Claim 7; Page 72-73; 103pp; English.
XX
CC   The invention relates to Willebrand Factor A domain related-protein
CC   (WARP) which is a member of von Willebrand Factor A (VA)-domain protein
CC   superfamily of extracellular matrix (ECM) proteins. WARP is used as a
CC   molecular marker, used for detecting a loss of ECM integrity in an animal
CC   subject, monitoring repair, regeneration or other disease processes in an
CC   animal subject and detecting a disease condition or a propensity for the
CC   development of a disease condition in an animal subject. The invention is
CC   useful for the manufacture of a medicament in the treatment of a disease
CC   condition of the ECM. The disease condition involves the cartilage, and
CC   is preferably arthritis. The invention is also used in gene therapy. The
CC   present sequence is human VA domain
XX
SQ   Sequence 180 AA;

Alignment Scores:
Pred. No.:                           Length:        180
Score:              4.51e-69         Matches:       178
Percent Similarity: 100.0%           Conservative:    0
Best Local Similarity: 100.0%        Mismatches:      0
Query Match:        86.0%            Indels:          0
DB:                                  Gaps:            6

US-10-699-035A-1 (1-537) x AAE32500 (1-180)

Qy      1 GGGGACCTGATGTTCCTGCTGGACAGCTCAGCCGGTCTCCACTACGAGTTCTCCCGG   60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      2 GlyAspLeuMetPheLeuLeuAspSerSerAlaSerValSerHisTyrGluPheSerArg  21

Qy     61 GTTCGGGAGTTTGTGGGGCAGCTGGTGCTCCACTGCCCCTGGGCACCGGGGCCCTGCGT  120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     22 ValArgGluPheValGlyGlnLeuValLeuAlaProLeuProLeuGlyThrGlyAlaLeuArg  41

Qy    121 GCCAGTCGTGGTGCACGTGGGCAGTCGGCCATACACCGAGTTCCCCTTCGGCCAGCACAGC  180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     42 AlaSerLeuValHisValGlySerArgProTyrThrGluPheProPheGlyGlnHisSer  61

Qy    181 TCGGGTGAGGCTGCCCAGGATGCGGTCCGGTGCTTCTCGCCCAGCGCCATGGTGACACCCAC  240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     62 SerGlyGluAlaAlaGlnAspAlaValArgAlaSerAlaGlnArgMetGlyTyrAspThrHis  81

Qy    241 ACTGGCCTGGCCGCTGGTCTATGCCAAGGAACAGCTGTTTGCTGAAGCATCAGGTGCCCGG  300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     82 ThrGlyLeuAlaLeuValTyrAlaLysGluGlnLeuPheAlaGluAlaSerGlyAlaArg  101

Qy    301 CCAGGGGTGCCCAAAGTGCTGTGTGGGTGACAGATGGCGGCTTCCAGCGACCCTGTGGGC  360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    102 ProGlyValProLysValLeuValTrpValThrAspGlyGlySerSerAspProValGly  121

Qy    361 CCCCCCATGCAGGAGCTCAAGGACCTGGGCGTCACCGTGTTCAGTCAGCACGGGCCGA  420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    122 ProProMetGlnGluLeuLysAspLeuGlyValThrValPheIleValSerThrGlyArg  141

Qy    421 GGCAACTTCCTGGAGCTGTCAGCCGCTGCCTCAGCCCCTGCCGAGAAGCACCTGCACTTT  480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    142 GlyAsnPheLeuGluLeuSerAlaAlaAlaSerAlaProAlaGluLysHisLeuHisPhe  161

Qy    481 GTGGACTGGATGACCTGCACATCATTGTCCAAGAGCTGAGGGGCTCCATTCTC  534
          |||||||||||||||||||||||||||||||||||||||||||||||||
Db    162 ValAspValAspAspLeuHisIleIleValGlnGluLeuArgGlySerIleLeu  179

RESULT 2
AAB87344
ID   AAB87344 standard; protein; 215 AA.
```

```
XX
AC   AAB87344;
XX
DT   22-MAY-2001 (first entry)
XX
DE   Human gene 3 encoded secreted protein HNTEO78, SEQ ID NO:85.
XX
KW   Human; secreted protein; proliferative disorder; cancer; tumour;
KW   foetal abnormality; developmental abnormality; haematopoietic disorder;
KW   immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW   inflammation; allergy; neurological disorder; Alzheimer's disease;
KW   Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW   skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW   cardiovascular disorder; angiogenic disorder; kidney disorder;
KW   gastrointestinal disorder; pregnancy-related disorder;
KW   endocrine disorder; infection; wound healing; vulnerary; cell culture;
KW   chemotaxis; food additive; binding partner identification.
XX
OS   Homo sapiens.
XX
PN   WO200118022-A1.
XX
PD   15-MAR-2001.
XX
PF   31-AUG-2000; 2000WO-US024008.
XX
PR   03-SEP-1999;  99US-0152315P.
PR   03-SEP-1999;  99US-0152317P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ni J,  Baker KP,  Birse CE,  Fiscella M,  Komatsoulis GA,  Rosen CA;
PI   Soppet DR,  Young PE,  Ebner R,  Duan DR,  Olsen HS,  Lafleur DW;
PI   Moore PA,  Shi Y,  Wei Y,  Florence KA;
XX
DR   WPI; 2001-203081/20.
DR   N-PSDB; AAF91860.
XX
PT   Nucleic acid molecules encoding human secreted proteins, used in
PT   preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
PT   Parkinson's diseases and cancers.
XX
PS   Claim 11; Page 532-533; 607pp; English.
XX
CC   AAF91858-AAF91929 represent cDNAs corresponding to 52 human secreted
CC   protein genes, and AAB87342-AAB87413 represent the proteins they encode.
CC   AAB87414-AAB87454 represent human secreted protein fragments. The genes
CC   and their corresponding secreted proteins are useful for preventing,
CC   treating or ameliorating medical conditions, e.g., by protein or gene
CC   therapy. Pathological conditions can be diagnosed by determining the
CC   amount of the new protein in a sample or by determining the presence of
CC   mutations in the new genes. Specific uses are described for each of the
CC   52 genes, based on the tissues in which they are most highly expressed,
CC   and include developing products for the diagnosis or treatment of
CC   proliferative disorders, cancer, tumours, foetal and developmental
CC   abnormalities, haematopoietic disorders, diseases of the immune system,
CC   AIDS, autoimmune diseases (e.g., rheumatoid arthritis), inflammation,
CC   allergies, neurological disorders (e.g., Alzheimer's disease,
CC   Parkinsons's disease), cognitive disorders, schizophrenia, asthma, skin
CC   disorders (e.g. psoriasis), sepsis, diabetes, atherosclerosis,
CC   cardiovascular disorders, angiogenic disorders, kidney disorders,
CC   gastrointestinal disorders, pregnancy-related disorders, endocrine
CC   disorders, and infections. The proteins can also be used to aid wound
CC   healing and epithelial cell proliferation, to prevent skin aging due to
CC   sunburn, to maintain organs before transplantation, for supporting cell
CC   culture of primary tissues, to regenerate tissues, to identify their
CC   cognate ligands or binding partners, and in chemotaxis, and can be used
CC   as a food additive or preservative to modify storage properties.
CC   Antibodies specific for a protein of the invention can be used in
CC   alleviating symptoms associated with the disorders mentioned above, and
CC   in diagnostic immunoassays e.g., radioimmunoassay or enzyme linked
CC   immunosorbent assay (ELISA). The present sequence represents a human
CC   secreted protein of the invention
```

CC   subject, monitoring repair, regeneration or other disease processes in an
CC   animal subject and detecting a disease condition or a propensity for the
CC   development of a disease condition in an animal subject. The invention is
CC   useful for the manufacture of a medicament in the treatment of a disease
CC   condition of the ECM. The disease condition involves the cartilage, and
CC   is preferably arthritis. The invention is also used in gene therapy. The
CC   present sequence is human VA domain
XX
SQ   Sequence 180 AA;

Query Match   100.0%;   Score 913;   DB 6;   Length 180;
Best Local Similarity 100.0%;   Pred. No. 1.6e-94;
Matches 180; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPFGQH 60
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1 RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPFGQH 60

Qy   61 SSGBAAQDAVRASAQRMGDTHTGLALVYAKEQLFARASGARPGVPKVLVWVTDGGSSDPV 120
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 SSGBAAQDAVRASAQRMGDTHTGLALVYAKEQLFARASGARPGVPKVLVWVTDGGSSDPV 120

Qy 121 GPPMQBLKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFVDVDDLHIIVQELRGSILD 180
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 GPPMQBLKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFVDVDDLHIIVQELRGSILD 180

RESULT 2
AAB87344
ID   AAB87344 standard; protein; 215 AA.
XX
AC   AAB87344;
XX
DT   22-MAY-2001 (first entry)
XX
DE   Human gene 3 encoded secreted protein HNTEO78, SEQ ID NO:85.
XX
KW   Human; secreted protein; proliferative disorder; cancer; tumour;
KW   foetal abnormality; developmental abnormality; haematopoietic disorder;
KW   immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW   inflammation; allergy; neurological disorder; Alzheimer's disease;
KW   Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW   skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW   cardiovascular disorder; angiogenic disorder; kidney disorder;
KW   gastrointestinal disorder; pregnancy-related disorder;
KW   endocrine disorder; infection; wound healing; vulnerary; cell culture;
KW   chemotaxis; food additive; binding partner identification.
XX
OS   Homo sapiens.
XX
PN   WO200118022-A1.
XX
PD   15-MAR-2001.
XX
PF   31-AUG-2000; 2000WO-US024008.
XX
PR   03-SEP-1999; 99US-0152315P.
PR   03-SEP-1999; 99US-0152317P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ni J, Baker KP, Birse CE, Fiscella M, Komatsoulis GA, Rosen CA;
PI   Soppet DR, Young PB, Ebner R, Duan DR, Olsen HS, Lafleur DW;
PI   Moore PA, Shi Y, Wei Y, Florence KA;
XX
DR   WPI; 2001-203081/20.
DR   N-PSDB; AAF91860.
XX
PT   Nucleic acid molecules encoding human secreted proteins, used in
PT   preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
PT   Parkinson's diseases and cancers.
XX
PS   Claim 11; Page 532-533; 607pp; English.

XX
CC   AAF91858-AAF91929 represent cDNAs corresponding to 52 human secreted
CC   protein genes, and AAB87342-AAB87413 represent the proteins they encode.
CC   AAB87414-AAB87454 represent human secreted protein fragments. The genes
CC   and their corresponding secreted proteins are useful for preventing,
CC   treating or ameliorating medical conditions, e.g., by protein or gene
CC   therapy. Pathological conditions can be diagnosed by determining the
CC   amount of the new protein in a sample or by determining the presence of
CC   mutations in the new genes. Specific uses are described for each of the
CC   52 genes, based on the tissues in which they are most highly expressed,
CC   and include developing products for the diagnosis or treatment of
CC   proliferative disorders, cancer, tumours, foetal and developmental
CC   abnormalities, haematopoietic disorders, diseases of the immune system,
CC   AIDS, autoimmune diseases (e.g., rheumatoid arthritis), inflammation,
CC   allergies, neurological disorders (e.g. Alzheimer's disease,
CC   Parkinsons's disease), cognitive disorders, schizophrenia, asthma, skin
CC   disorders (e.g., psoriasis), sepsis, diabetes, atherosclerosis,
CC   cardiovascular disorders, angiogenic disorders, kidney disorders,
CC   gastrointestinal disorders, pregnancy-related disorders, endocrine
CC   disorders, and infections. The proteins can also be used to aid wound
CC   healing and epithelial cell proliferation, to prevent skin aging due to
CC   sunburn, to maintain organs before transplantation, to regenerate cell
CC   culture of primary tissues, to identify their
CC   cognate ligands or binding partners, and in chemotaxis, and can be used
CC   as a food additive or preservative to modify storage properties.
CC   Antibodies specific for a protein of the invention can be used in
CC   alleviating symptoms associated with the disorders mentioned above, and
CC   in diagnostic immunoassays e.g., radioimmunoassay or enzyme linked
CC   immunosorbent assay (ELISA). The present sequence represents a human
CC   secreted protein of the invention
XX
SQ   Sequence 215 AA;

Query Match   100.0%;   Score 913;   DB 4;   Length 215;
Best Local Similarity 100.0%;   Pred. No. 2e-94;
Matches 180; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPFGQH 60
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   32 RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPFGQH 91

Qy   61 SSGBAAQDAVRASAQRMGDTHTGLALVYAKEQLFARASGARPGVPKVLVWVTDGGSSDPV 120
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   92 SSGBAAQDAVRASAQRMGDTHTGLALVYAKEQLFARASGARPGVPKVLVWVTDGGSSDPV 151

Qy 121 GPPMQBLKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFVDVDDLHIIVQELRGSILD 180
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 152 GPPMQBLKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFVDVDDLHIIVQELRGSILD 211

RESULT 3
ABG65347
ID   ABG65347 standard; protein; 215 AA.
XX
AC   ABG65347;
XX
DT   27-AUG-2002 (first entry)
XX
DE   Human albumin fusion protein #2022.
XX
KW   Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW   human serum albumin; HSA; cancer; reproductive disorder;
KW   digestive disorder; immune disorder; endocrine disorder;
KW   haematopoietic disorder; neural disorder; connective disorder;
KW   cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW   immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW   neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW   osteopathic; antiarthritic.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177137-A1.

```
CC    anticonvulsant; antiarthritic; immunostimulant; immunosuppressant;
CC    cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;
CC    dermatological; immunosuppressive; antiinflammatory; antibacterial;
CC    antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The
CC    sequences can be used for determining the presence of or predisposition
CC    to, or preventing or treating pathological conditions associated with an
CC    ORFX-associated disorder. The nucleic acids can be used to express ORFX
CC    proteins in gene therapy vectors. The proteins and nucleic acids may be
CC    used to treat cancers, proliferative disorders, neurodegenerative
CC    disorders, osteoarthritis, graft vs host disease, cardiovascular disease,
CC    diabetes mellitus, hypertension, hypothyroidism, cholesterol ester
CC    storage, systemic lupus erythematosus, severe combined immunodeficiency
CC    (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune
CC    disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and
CC    cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to
CC    enhance coagulation; to inhibit thrombosis; and as a contraceptive
XX
SQ    Sequence 299 AA;

                                    WO 2006116022 A1

Alignment Scores:
Pred. No.:
Score:                 6.32e-86
Percent Similarity:    1373.00              Length:              299
Best Local Similarity: 94.6%                Matches:             282
Query Match:           94.6%                Conservative:        0
DB:                    57.7%                Mismatches:          8
                       3                    Indels:              8
                                            Gaps:                3

US-10-699-035A-5 (1-1254) x AAB42581 (1-299)

Qy      3 GCTCCCCTGGACGGCGCTCGGCCCTGGCCTGGCCTTCGGCGCTTCCGGCTGGCGCTGGCCGGGCTGGCCGTGGCGCGGAGCGG   62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||  -------T  26
Db      9 AlaProLeuAspGlyAlaArg-LeuAlaLeuSerLeuArg-TrpArgTrpArg------T   26

Qy     63 CGCGGAGCGCGCGGTCCACCAGCATCAGCCCCCCGAGGGACCTGATGTTCCTGCTGACAG   122
          |||||||                  |||||||||||||||||||||||||||
Db     26 hrProAspCys--ProProAlaSerAlaProGlu--AspLeuMetPheLeuLeuLeuAspSe   44

Qy    123 CTCAGCCAGCGTCTCACTACGAGTTCTCCCGGGTTCGGGAGTTTGTGGGGCAGCTGGT   182
          ||||||||||||||||||||||||||||||||   ||||||||||||||||||||
Db     44 rSerAlaSerValSerHisTyrGluPheSerArgValArgGluPheValGlyGlnLeuVa   64

Qy    183 GGCTCCACTGCCCCTGGGCACCGGAGCCCGCCCTGCGTGCCCAGTCTGGTGCACGTGGGCAGTCG   242
          ||||||||||        |||||||||||||||||||||||||||||||||||||||
Db     64 lAlaProLeuProLeuAlaPro***AlaLeuArgAlaSerLeuValHisValGlySerAr   84

Qy    243 GCCATACACCGAGTTCCCCTTCGGCCAGCACAGCTCGGGTGAGGCTGCCAGGATGCGGT   302
          |||||||                  ||||||||||||||||||||||||||||
Db     84 gProTyrThrGluPheProPheGlyGlnHisSerSerGlyGluValAlaGlnAspAlaVa   104

Qy    303 GGCTGCTTCTGCCCAGCCGCCATGGGTGACACCCCACACTCGGCCTGGCGCCGGTCTATGCCAA   362
          ||||||||                    ||||||||||||||||||||||||||||
Db    104 lArgAlaSerAlaGlnArgMetGlyAspMetHisThrGlyLeuAlaLeuValTyrAlaLy   124

Qy    363 GGAACAGCTGTTTGCTGAAGCATCAGGTGCCCAGGGGTGCCCAAAGTGCTGGTGTG   422
          ||||||||                    ||||||||||||||||||||||||||
Db    124 sGluGlnLeuPheAlaGluAlaSerGlyAlaSerGlyValAlaArgProGlyValAlaLeuValLeuValThr   144

Qy    423 GGTGACAGATGGCGGCTCCAGCGACCCTGTGGGCCCCCATGCAGGAGCTCAAGGACCT   482
          ||||||||                    ||||||||||||||||||||||||||
Db    144 pValThrAspGlyGlySerSerAspProValGlyProMetGlnGluLeuLysAspLe   164

Qy    483 GGGGCGTCACCGTTCATTGTCAGCACCACCGGCCGAGGCAACTTCCTGGAGCTGTCAGCCGC   542
          ||||||||                    ||||||||||||||||||||||||
Db    164 uGlyValThrValPheIleValSerThrThrGlyArgGlyAsnPheLeuGluLeuSerAlaAl   184

Qy    543 TGCCTCAGCCCCCTGCCGAGAGCACCACTGCCACTTGTGGACTGGATGACCTGCACATCAT   602
          ||||||||                    ||||||||||||||||||||||
Db    184 aAlaSerAlaProAlaGluLeuHisHisCysHisLeuTrpThrGlyMetThrCysThrSerSer   204

Qy    603 TGTCCAAGAGCTGAGGGGCTTCCATCTC---GCCGATGCGCGCCGACCAGCTCCATGCCAC   659
          ||||||||                    |||||||||||||||||||
Db    204 eValGlnGluLeuArgGlySerIleLeuLeuAspAlaMetArgProGlnGlnLeuHisAlaTh   224
```

```
Qy    660 GGAGATCACGTCCAGCGGCTTCCGGCTGGCCGCCGCCACCCTGCGCACCGAGACTCCGG   719
          |||||||||||||||||||||||||||||||||||||||||||||||||
Db    224 rGlueIleThrSerSerGlyPheArgLeuAlaTrpProProLeuThrAlaAspSerGl   244

Qy    720 CTACTATGTGCTGGAGCTGGTGCCCAGCGACCGGCCGGGGCTGCAAGACGCCAGCAGCT   779
          ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    244 yTyrTyrValLeuGluLeuValProSerAlaGlnProGlyAlaAlaArgArgGlnGlnLe   264

Qy    780 GCCAGGGAACGCCACGGACTGGATCGGGCCGGGGCCTCGACCGGACACGGACTACGACGT   839
          |||||||||||||||||||||||||||||||||||||||||||||||||||
Db    264 uProGlyAsnAlaThrAspTrpIleTrpProGlyProGlyLeuAspProAspThrAspTyrAspVa   284

Qy    840 GGGGCTAGTGCCTAGTCCAACGTGCGCCTTCCTGAGGCCCCAGATC   885
          ||||||||||||||||||||||||||||||||||||||||
Db    284 lAlaLeuValProGluSerAsnValArgLeuLeuArgProGlnIle   299
```

```
RESULT 9
AAB87344
ID    AAB87344  standard; protein; 215 AA.
XX
AC    AAB87344;
XX
DT    22-MAY-2001  (first entry)
XX
DE    Human gene 3 encoded secreted protein HNTEO78, SEQ ID NO:85.
XX
KW    Human; secreted protein; proliferative disorder; cancer; tumour;
KW    foetal abnormality; developmental abnormality; haematopoietic disorder;
KW    immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW    inflammation; allergy; neurological disorder; Alzheimer's disease;
KW    Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW    skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW    cardiovascular disorder; angiogenic disorder; kidney disorder;
KW    gastrointestinal disorder; pregnancy-related disorder;
KW    endocrine disorder; infection; wound healing; vulnerary; cell culture;
KW    chemotaxis; food additive; binding partner identification.
OS    Homo sapiens.
XX
PN    WO200118022-A1.
XX
PD    15-MAR-2001.
XX
PF    31-AUG-2000; 2000WO-US024008.
XX
PR    03-SEP-1999;    99US-0152315P.
PR    03-SEP-1999;    99US-0152317P.
XX
PA    (HUMA-) HUMAN GENOME SCI INC.
XX
PI    Ni J, Baker KP, Birse CE, Fiscella M, Komatsoulis GA, Rosen CA,
PI    Soppet DR, Young PE, Ebner R, Duan DR, Moore PA, Olsen HS, Lafleur DW,
PI    Moore PA, Shi Y, Wei Y, Florence KA;
XX
DR    WPI; 2001-203081/20.
DR    N-PSDB; AAF91860.
XX
PT    Nucleic acid molecules encoding human secreted proteins, used in
PT    preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
PT    Parkinson's diseases and cancers.
XX
PS    Claim 11; Page 532-533; 607pp; English.
XX
CC    AAF91858-AAF91929 represent cDNAs correeponding to 52 human secreted
CC    protein genes, and AAF91929 represent the proteins they encode.
CC    AAB87342-AAB87413 represent human secreted protein fragments. The genes
CC    AAB87414-AAB87454 represent human secreted proteins are useful for preventing,
CC    and their corresponding secreted proteins are useful for preventing,
CC    treating or ameliorating medical conditions, e.g. by protein or gene
CC    therapy. Pathological conditions can be diagnosed by determining the
CC    amount of the new protein in a sample or by determining the presence of
CC    mutations in the new genes. Specific uses are described for each of the
CC    52 genes, based on the tissues in which they are most highly expressed,
CC    and include developing products for the diagnosis or treatment of
```

```
              GenCore version 5.1.7
        Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on:      February 13, 2006, 13:10:29 ; Search time 9.08696 Seconds
                                            (without alignments)
                                  603.637 Million cell updates/sec

Title:         US-10-699-035A-6
Perfect score: 2154
Sequence:      1 MLPWTALGLALSLRLALARS........RPRPRPVPRAPTPGTASREP 418

Scoring table: BLOSUM62
               Gapop 10.0 , Gapext 0.5

Searched:      97014 seqs, 13122538 residues

Total number of hits satisfying chosen parameters:      97014

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :   Published Applications AA New:*
             1: /cgm2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
             2: /cgm2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
             3: /cgm2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
             4: /cgm2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
             5: /cgm2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
             6: /cgm2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
             7: /cgm2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:*
             8: /cgm2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*

     Pred. No. is the number of results predicted by chance to have a
     score greater than or equal to the score of the result being printed,
     and is derived by analysis of the total score distribution.
```

SUMMARIES

Result No.	Score	% Query Match	Match Length	DB	ID	Description
1	2130.5	98.9	445	6	US-10-453-372-2	Sequence 2, Appli
2	421.5	19.6	3063	7	US-11-186-284-26	Sequence 26, Appl
3	401	18.6	517	7	US-11-169-041-160	Sequence 160, App
4	253.5	11.8	915	6	US-10-131-826A-294	Sequence 294, App
5	253.5	11.8	956	7	US-11-113-424-39	Sequence 39, Appl
6	194	9.0	214	7	US-11-192-449-6	Sequence 6, Appli
7	194	9.0	214	7	US-11-192-449-9	Sequence 9, Appli
8	185	8.6	214	6	US-10-192-449-5	Sequence 5, Appli
9	184	8.5	678	6	US-10-063-703-34	Sequence 34, Appl
10	184	8.5	678	7	US-11-102-240-34	Sequence 34, Appl
11	175	8.1	709	6	US-10-453-372-186	Sequence 186, App
12	174	8.1	709	6	US-10-453-372-180	Sequence 180, App
13	174	8.1	1152	7	US-11-080-026-4	Sequence 4, Appli
14	173	8.0	709	6	US-10-453-372-182	Sequence 182, App
15	172.5	8.0	1167	6	US-10-601-368-18	Sequence 18, Appl
16	169	7.8	3570	6	US-10-453-372-178	Sequence 178, App
17	169	7.8	3570	6	US-10-453-372-196	Sequence 196, App
18	169	7.8	3570	6	US-10-453-372-198	Sequence 198, App
19	169	7.8	3570	6	US-10-453-372-200	Sequence 200, App
20	169	7.8	3570	6	US-10-453-372-202	Sequence 202, App
21	169	7.8	3570	6	US-10-453-372-204	Sequence 204, App
22	169	7.8	3570	6	US-10-453-372-206	Sequence 206, App
23	168	7.8	709	6	US-10-453-372-184	Sequence 184, App
24	168	7.8	3568	6	US-10-453-372-194	Sequence 194, App
25	162.5	7.5	847	6	US-10-995-561-634	Sequence 634, App
26	162.5	7.5	1259	6	US-10-995-561-625	Sequence 625, App
27	162.5	7.5	1286	6	US-10-995-561-628	Sequence 628, App
28	162.5	7.5	1341	6	US-10-995-561-621	Sequence 621, App
29	162.5	7.5	2217	7	US-11-193-561-38	Sequence 38, Appl
30	162.5	7.5	2217	7	US-11-193-771-38	Sequence 38, Appl
31	162.5	7.5	2217	7	US-11-193-789-38	Sequence 38, Appl
32	162.5	7.5	2217	7	US-11-193-806-38	Sequence 38, Appl
33	162.5	7.5	2217	7	US-11-193-857-38	Sequence 38, Appl
34	162.5	7.5	2330	7	US-11-193-561-21	Sequence 21, Appl
35	162.5	7.5	2330	7	US-11-193-771-21	Sequence 21, Appl
36	162.5	7.5	2330	7	US-11-193-789-21	Sequence 21, Appl
37	162.5	7.5	2330	7	US-11-193-806-21	Sequence 21, Appl
38	162.5	7.5	2330	7	US-11-193-857-21	Sequence 21, Appl
39	162.5	7.5	2355	6	US-10-995-561-623	Sequence 623, App
40	162.5	7.5	2355	6	US-10-995-561-627	Sequence 627, App
41	162.5	7.5	2355	7	US-11-193-561-19	Sequence 19, Appl
42	162.5	7.5	2355	7	US-11-193-771-19	Sequence 19, Appl
43	162.5	7.5	2355	7	US-11-193-789-19	Sequence 19, Appl
44	162.5	7.5	2355	7	US-11-193-806-19	Sequence 19, Appl
45	162.5	7.5	2355	7	US-11-193-857-19	Sequence 19, Appl

ALIGNMENTS

```
RESULT 1
US-10-453-372-2
; Sequence 2, Application US/10453372
; Publication No. US2006000323A1
; GENERAL INFORMATION:
;   APPLICANT: Alsobrook, et al.
;   TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METH
;   FILE REFERENCE: 21402-589 A
;   CURRENT APPLICATION NUMBER: US/10/453,372
;   CURRENT FILING DATE: 2003-06-03
;   PRIOR APPLICATION NUMBER: 09/789390
;   PRIOR FILING DATE: 2001-02-23
;   PRIOR APPLICATION NUMBER: 60/185967
;   PRIOR FILING DATE: 2000-03-01
;   PRIOR APPLICATION NUMBER: 09/823187
;   PRIOR FILING DATE: 2001-03-29
;   PRIOR APPLICATION NUMBER: 60/195792
;   PRIOR FILING DATE: 2000-03-10
;   PRIOR APPLICATION NUMBER: 09/839446
;   PRIOR FILING DATE: 2001-03-19
;   PRIOR APPLICATION NUMBER: 60/199476
;   PRIOR FILING DATE: 2000-03-25
;   PRIOR APPLICATION NUMBER: 09/863776
;   PRIOR FILING DATE: 2001-05-23
;   PRIOR APPLICATION NUMBER: 60/208263
;   PRIOR FILING DATE: 2000-05-31
;   PRIOR APPLICATION NUMBER: 09/939398
;   PRIOR FILING DATE: 2001-08-24
;   PRIOR APPLICATION NUMBER: 60/227800
;   PRIOR FILING DATE: 2000-08-25
;   Remaining Prior Application data removed - See File Wrapper or PALM.
;   NUMBER OF SEQ ID NOS: 1609
;   SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 2
;   LENGTH: 445
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-453-372-2

  Query Match             98.9%;  Score 2130.5;  DB 6;  Length 445;
  Best Local Similarity   93.9%;  Pred. No. 3.9e-161;
  Matches  418;  Conservative    0;  Mismatches    0;  Indels   27;  Gaps    1;

Qy          1 MLPWTALGLALSLRLALARSGAERGPPASAPRGDLMFLLDSSASVSHYEFSRVREFVGQL 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MLPWTALGLALSLRLALARSGAERGPPASAPRGDLMFLLDSSASVSHYEFSRVREFVGQL 60

Qy         61 VAPLPLGTGALRASLVHVGSRPYTTBPFFGQHSSGEAAQDAVRASAQRMGDTHTGLALVYA 120
```

```
Db  498 TKVEDIIEAINTPPYRGGSTNTGKAMTYVREKIFVPSKGSRSNVPKVMILITDGKSSDAF 557
            |||||||||
Qy  152 GPPMQELKDLGVTVFIVSTGRGNFLELSAAAAPAEKHLHFV-DVDDLHIIVQBLRGSI- 209
            :|:          ::|:
Db  558 RDPAIKLRNSDVBIPAVGVKDAVRSELEAIASPPAETHVFTVEDPDAFQRISPELTQSIC 617
Qy  210 ------LDAMR------PQQLHATEITSSGFRLAWPPL----------LTADSGYYV 244
            |::         :|:|::|||
Db  618 LRIEQELAAIKKCAYVPPKDLSFSEVTSYGFKTNWSPAGENVFSYHITYKEAAGDDEVTV 677
Qy  245 LE-------LVPSAQP------------------------GAARRQQLPGNATD 267
            ::|                              |:  :
Db  678 VEPASSTSVVLSSLKPETLYLVNVTAEYEDGFSIPLAGEETTBBVKGAPRNLKVTDFTTD 737
Qy  268 -----WIWA----------------------------GLDPDTDYDVALVPESN 288
            |:||
Db  738 SFKITWTQAPGRVLRCRIIYRPVAGGESREVTTPNQRRTLENLIPDTKYBVSVIPEYF 797
Qy  289 VRLLRPQILRVRTRPEEAGPERIVISHARPRSLRVSWAPALGSAAALGYHVQFGPLRGGE 348
            :::|||:|
Db  798 SGPGTPLTGNAATEEVRGNPRDLRVSDPTTSMKLSWSGAPGKVKQ--YLVTYTPVAGGE 855
Qy  349 AQRVEVPAGRNCTTLQGLAPGTAYLLVTVTAAFRSGRESALSAKACT 394
            ||:
Db  856 TQEVTVRGDTNTVLQGLKEGTQYALSVTALYASGAGDALFGEGTT 901
```

```
Db      ||||||||||||||||||||||||||||||||||||||||
     61 VAPLPLGTGALRASLVHVGSRPYTEFPPGQHSSGEAAQDAVRASAQRMGDTHTGLALVYA 120
Qy  121 KEQLFAEASGARPGVPKVLVWVTDGGSSDPVGPPMQELKDLGVTVFIVSTGRGNFLELSA 180
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 KEQLFAEASGARPGVPKVLVWVTDGGSSDPVGPPMQELKDLGVTVFIVSTGRGNFLELSA 180
Qy  181 AASAPAEKHLHFVDVDDLHIIVQELRGSILDAMRPQQLHATEITSSGFRLAWPPLLTADS 240
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  181 AASAPAEKHLHFVDVDDLHIIVQELRGSILDAMRPQQLHATEITSSGFRLAWPPLLTADS 240
Qy  241 GYYVLELVPSAQPGAARRQQLPGNATDWIWAGLDPDTDYDVALVPESNVRLLRPQILRVR 300
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  241 GYYVLELVPSAQPGAARRQQLPGNATDWIWAGLDPDTDYDVALVPESNVRLLRPQILRVR 300
Qy  301 TR------------------PEEAGPERIVISHARPRSLRVSWAPALGSAA 333
         ||                  ||||||||||||||||||||||||||||||
Db  301 TRPGEAGPGASGPESGAGPAPTQLAALPAPEEAGPERIVISHARPRSLRVSWAPALGSAA 360
Qy  334 ALGYHVQFGPLRGGEAQRVEVPAGRNCTTLQGLAPGTAYLLVTVTAAFRSGRESALSAKAC 393
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  361 ALGYHVQFGPLRGGEAQRVEVPAGRNCTTLQGLAPGTAYLLVTVTAAFRSGRESALSAKAC 420
Qy  394 TPDGPRPRPRPVPRAPTPGTASREP 418
         |||||||||||||||||
Db  421 TPDGPRPRPRPVPRAPTPGTASREP 445
```

RESULT 2
US-11-186-284-26
; Sequence 26, Application US/11186284
; Publication No. US2005026693A1
; GENERAL INFORMATION:
;   APPLICANT: Millennium Pharmaceuticals, Inc.
;   APPLICANT: Berger, Allison
;   APPLICANT: Guillemette, Tracy L.
;   APPLICANT: Kamatkar, Shubhangi
;   APPLICANT: Schlegel, Robert
;   APPLICANT: Monahan, John E.
;   APPLICANT: Thibodeau, Stephen N.
;   APPLICANT: Burgart, Lawrence J.
;   TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND
;   TITLE OF INVENTION: METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND
;   TITLE OF INVENTION: THERAPY OF COLON CANCER
;   FILE REFERENCE: MPM01-029P2RNM
;   CURRENT APPLICATION NUMBER: US/11/186,284
;   CURRENT FILING DATE: 2005-07-21
;   PRIOR APPLICATION NUMBER: US/10/301,822
;   PRIOR FILING DATE: 2002-11-21
;   PRIOR APPLICATION NUMBER: US 60/339,971
;   PRIOR FILING DATE: 2001-12-10
;   PRIOR APPLICATION NUMBER: US 60/361,978
;   PRIOR FILING DATE: 2002-03-05
;   PRIOR APPLICATION NUMBER: US 60/381,988
;   PRIOR FILING DATE: 2002-05-20
;   NUMBER OF SEQ ID NOS: 228
;   SOFTWARE: FastSEQ for Windows Version 4.0
;   SEQ ID NO 26
;   LENGTH: 3063
;   TYPE: PRT
;   ORGANISM: Homo Sapiens
US-11-186-284-26

  Query Match   19.6%;   Score 421.5; DB 7; Length 3063;
  Best Local Similarity 27.5%;   Pred. No. 5.5e-25;
  Matches 128; Conservative 59; Mismatches 174; Indels 105; Gaps 9;

```
Qy   32 RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEPPPGQH 91
          : |:|:|||        ::|:
Db  438 KADIVFLVDGSYSIGIANFVKVRAFLEVLVKSFEISPNRVQISLVQYSRDPHTEFTLKKF 497
Qy   92 SSGEAAQDAVRASAQRMGDTHTGLALVYAKEQLFAEASGARPGVPKVLVWVTDGGSSDPV 151
          :  :||:
```

RESULT 3
US-11-169-041-160
; Sequence 160, Application US/11169041
; Publication No. US20060019284A1
; GENERAL INFORMATION:
;   APPLICANT: Bristol-Myers Squibb Company
;   TITLE OF INVENTION: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF
;   TITLE OF INVENTION: COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE
;   TITLE OF INVENTION: KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN LUNG CANCER
;   TITLE OF INVENTION: CELLS
;   FILE REFERENCE: 10001 NP
;   CURRENT APPLICATION NUMBER: US/11/169,041
;   CURRENT FILING DATE: 2005-06-28
;   PRIOR APPLICATION NUMBER: 60/584,405
;   PRIOR FILING DATE: 2004-06-30
;   NUMBER OF SEQ ID NOS: 527
;   SOFTWARE: PatentIn version 3.2
;   SEQ ID NO 160
;   LENGTH: 517
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-169-041-160

  Query Match   18.6%;   Score 401; DB 7; Length 517;
  Best Local Similarity 30.0%;   Pred. No. 2.2e-24;
  Matches 114; Conservative 61; Mismatches 179; Indels 26; Gaps 6;

```
Qy   36 MPLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPPGQHSSGE 95
          |||:|
Db  143 MFLVDGSYSIGIANFVKVRAFLEVLVKSFEISPNRVQISLVQYSRDPHTEFTLKKFTKVE 202
Qy   96 AAQDAVRASAQRMGDTHTGLALVYAKEQLFAEASGARPGVPKVLVWVTDGGSSDPVGPPM 155
          
Db  203 DIIEAINTPPYRGGSTNTGKAMTYVREKIFVPSKGSRSNVPKVMILITDGKSSDAFRDPA 262
Qy  156 QELKDLGVTVFIVSTGRGNFLELSAAAAPAEKHLHFV-DVDDLHIIVQBLRGSI------ 209
          
Db  263 IKLRNSDVBIPAVGVKDAVDSELEAIASPPAETHVFTVEDPDAFQRISPELTQSICLRIB 322
Qy  210 --LDAMR------PQQLHATEITSSGFRLAWPPLLTADSGYVLELVPSAQPGAARRQQL 261
          
Db  323 QELAAIKKCAYVPPKDLSFSEVTSYGFKTNWSPAGENVFSYHI----TYKEAAGDDEV 376
Qy  262 ----PGNATDWIWAGLDPDTDYDVALVPESNVRLLRPQILRVRTRPEEAGPERIVISHAR 317
          
Db  377 TVVEPASSTSVVLNSLKPETLYLVNVTAEYEDGFSIPLAGEETTBBVKGAPRNLKVTDET 436
```

```
                    GenCore version 5.1.7
            Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search., using sw model

Run on:      February 13, 2006, 13:10:29 ; Search time 3.91304 Seconds
                                           (without alignments)
                                           603.637 Million cell updates/sec

Title:           US-10-699-035A-2
Perfect score:   913
Sequence:        1 RGDLMFLLDSSASVSHYEFS.........FVDVDDLHIIVQELRGSILD 180

Scoring table:   BLOSUM62
                 Gapop 10.0 , Gapext 0.5

Searched:        97014 seqs, 13122538 residues

Total number of hits satisfying chosen parameters:       97014

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :       Published Applications AA New:*
                 1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
                 2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
                 3: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
                 4: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
                 5: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
                 6: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
                 7: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:*
                 8: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.
```

SUMMARIES

Result No.	Score	% Match	Query Match Length	DB	ID	Description
1	913	100.0	445	6	US-10-453-372-2	Sequence 2, Appli
2	263.5	28.9	3063	7	US-11-186-284-26	Sequence 26, Appl
3	257.5	28.2	517	7	US-11-169-041-160	Sequence 160, App
4	251.5	27.5	915	6	US-10-131-826A-294	Sequence 294, App
5	251.5	27.5	956	7	US-11-113-424-39	Sequence 39, App
6	194	21.2	214	7	US-11-192-449-6	Sequence 6, Appli
7	194	21.2	214	7	US-11-192-449-9	Sequence 9, Appli
8	185	20.3	214	7	US-11-192-449-5	Sequence 5, Appli
9	183	20.0	678	6	US-10-063-703-34	Sequence 34, Appl
10	183	20.0	678	6	US-11-102-240-34	Sequence 34, Appl
11	163	17.9	709	6	US-10-453-372-186	Sequence 186, App
12	162.5	17.8	1152	7	US-11-080-026-4	Sequence 4, Appli
13	162	17.7	709	6	US-10-453-372-180	Sequence 180, App
14	162	17.7	3568	6	US-10-453-372-194	Sequence 194, App
15	162	17.7	3570	6	US-10-453-372-178	Sequence 178, App
16	162	17.7	3570	6	US-10-453-372-196	Sequence 196, App
17	162	17.7	3570	6	US-10-453-372-198	Sequence 198, App
18	162	17.7	3570	6	US-10-453-372-200	Sequence 200, App
19	162	17.7	3570	6	US-10-453-372-202	Sequence 202, App
20	162	17.7	3570	6	US-10-453-372-204	Sequence 204, App
21	162	17.7	3570	6	US-10-453-372-206	Sequence 206, App
22	162	17.6	709	6	US-10-453-372-182	Sequence 182, App
23	156	17.1	709	6	US-10-453-372-184	Sequence 184, App
24	150.5	16.5	1167	6	US-10-601-368-18	Sequence 18, Appli
25	149.5	16.4	182	6	US-10-601-368-25	Sequence 25, Appli
26	149.5	16.4	1141	6	US-10-601-368-24	Sequence 24, Appl
27	149.5	16.4	1166	6	US-10-601-368-22	Sequence 22, Appl
28	149.5	16.4	1188	6	US-10-601-368-21	Sequence 21, Ap
29	145.5	15.9	1147	6	US-10-453-372-4	Sequence 4, Appli
30	144.5	15.8	182	6	US-10-601-368-6	Sequence 6, Appli
31	144.5	15.8	1141	6	US-10-601-368-4	Sequence 7, Appli
32	144.5	15.8	1166	6	US-10-601-368-4	Sequence 4, Appli
33	144.5	15.8	1188	6	US-10-601-368-3	Sequence 3, App
34	144.5	15.8	1188	7	US-11-000-463-338	Sequence 338, App
35	144.5	15.8	1188	7	US-11-000-463-810	Sequence 810, App
36	144.5	15.8	2764	6	US-10-995-561-691	Sequence 691, App
37	144.5	15.8	2813	6	US-10-995-561-688	Sequence 688, App
38	144.5	15.8	2919	7	US-10-821-234-1133	Sequence 1133, Ap
39	133.5	14.6	1179	7	US-11-097-125-1	Sequence 1, Appli
40	133.5	14.6	1196	6	US-10-995-561-921	Sequence 921, App
41	133	14.6	184	7	US-10-665-658-7	Sequence 7, Appli
42	133	14.6	1170	7	US-11-080-026-2	Sequence 2, Appli
43	133	14.6	1170	7	US-11-107-028-4	Sequence 4, Appli
44	131	14.3	184	6	US-10-665-658-8	Sequence 8, Appli
45	128	14.0	1167	7	US-11-097-125-2	Sequence 2, Appli

ALIGNMENTS

```
RESULT 1
US-10-453-372-2

; Sequence 2, Application US/10453372
; Publication No. US20060003323A1
; GENERAL INFORMATION:
;   APPLICANT: Alsobrook, et al.
;   TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHO
;   FILE REFERENCE: 21402-589 A
;   CURRENT APPLICATION NUMBER: US/10/453,372
;   CURRENT FILING DATE: 2003-06-03
;   PRIOR APPLICATION NUMBER: 09/789390
;   PRIOR FILING DATE: 2001-02-23
;   PRIOR APPLICATION NUMBER: 60/185967
;   PRIOR FILING DATE: 2000-03-01
;   PRIOR APPLICATION NUMBER: 09/823187
;   PRIOR FILING DATE: 2001-03-29
;   PRIOR APPLICATION NUMBER: 60/195792
;   PRIOR FILING DATE: 2000-03-10
;   PRIOR APPLICATION NUMBER: 09/839446
;   PRIOR FILING DATE: 2001-03-19
;   PRIOR APPLICATION NUMBER: 60/199476
;   PRIOR FILING DATE: 2000-03-25
;   PRIOR APPLICATION NUMBER: 09/863776
;   PRIOR FILING DATE: 2001-05-23
;   PRIOR APPLICATION NUMBER: 60/208263
;   PRIOR FILING DATE: 2000-05-31
;   PRIOR APPLICATION NUMBER: 09/939398
;   PRIOR FILING DATE: 2001-08-24
;   PRIOR APPLICATION NUMBER: 60/227800
;   PRIOR FILING DATE: 2000-08-25
;   Remaining Prior Application data removed - See File Wrapper or PALM.
;   NUMBER OF SEQ ID NOS: 1609
;   SOFTWARE: CuraSeqlist version 0.1
; SEQ ID NO 2
;   LENGTH: 445
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-453-372-2

Query Match             100.0%;  Score 913;  DB 6;  Length 445;
Best Local Similarity   100.0%;  Pred. No. 1.4e-83;
Matches  180;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    1  RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEPPFGQH  60
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   32  RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEPPFGQH  91

Qy   61  SSGEAAQDAVRASAQRMGDTHTGLALVYAKEQLFARASGARPGVPKVLVWVTDGGSSDPV  120
```

```
Db     92  SSGERAAQDAVRASAQRMGDTHTGLALVYAKEQLPAEASGARPGVPKVLVWVTDGGSSDPV  151
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy    121  GPPMQELKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFVDVDDLHIIVQELRGSILD   180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    152  GPPMQELKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFVDVDDLHIIVQELRGSILD   211
```

RESULT 2
US-11-186-284-26
; Sequence 26, Application US/11186284
; Publication No. US20050266493A1
; GENERAL INFORMATION:
;   APPLICANT: Millennium Pharmaceuticals, Inc.
;   APPLICANT: Berger, Allison
;   APPLICANT: Guillemette, Tracy L.
;   APPLICANT: Kamatkar, Shubhangi
;   APPLICANT: Schlegel, Robert
;   APPLICANT: Monahan, John E.
;   APPLICANT: Thibodeau, Stephen N.
;   APPLICANT: Burgart, Lawrence J.
;   TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND
;   TITLE OF INVENTION: METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND
;   TITLE OF INVENTION: THERAPY OF COLON CANCER
;   FILE REFERENCE: MPM01-029P2RNM
;   CURRENT APPLICATION NUMBER: US/11/186,284
;   CURRENT FILING DATE: 2005-07-21
;   PRIOR APPLICATION NUMBER: US/10/301,822
;   PRIOR FILING DATE: 2002-11-21
;   PRIOR APPLICATION NUMBER: US 60/339,971
;   PRIOR FILING DATE: 2001-12-10
;   PRIOR APPLICATION NUMBER: US 60/361,978
;   PRIOR FILING DATE: 2002-03-05
;   PRIOR APPLICATION NUMBER: US 60/381,988
;   PRIOR FILING DATE: 2002-05-20
;   NUMBER OF SEQ ID NOS: 228
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 3063
;   TYPE: PRT
;   ORGANISM: Homo Sapiens
US-11-186-284-26

Query Match   28.9%; Score 263.5; DB 7; Length 3063;
Best Local Similarity 35.8%; Pred. No. 1.1e-17;
Matches   64; Conservative 30; Mismatches 84; Indels   1; Gaps   1;

```
Qy      1  RGDLMFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPPGQH    60
              ::|:|:|||:  ||: |: |:|  ||||:|         :: :|||   :|||:   :
Db    438  KADIVPLVDGSYSIGIANFVKVRAFLEVLVKSFEISPNRVQISLVQYSRDPHTEFTLKKF   497
Qy     61  SSGERAAQDAVRASAQRMGDTHTGLALVYAKEQLPAEASGARPGVPKVLVWVTDGGSSDPV  120
              :|:  ||  |:|||||  ||| |:: :| |   |  : :|:| |:|   : |||  :||:
Db    498  TKVEDIIEAINTPFYRGGSTNTGKAMTYVREKIFVPSKGSRSNVPKVMILITDGKSSDAF   557
Qy    121  GPPMQELKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFV-DVDDLHIIVQELRGSI    178
              ||||  |:|:|       | :|:|   ::|: |:|          |: : |   |||::  |
Db    558  RDPAIKLRNSDVEIFAVGVKDAVRSELEAIASPPAETHVFTVEDFDAFQRISFELTQSI    616
```

RESULT 3
US-11-169-041-160
; Sequence 160, Application US/11169041
; Publication No. US20060019284A1
; GENERAL INFORMATION:
;   APPLICANT: Bristol-Myers Squibb Company
;   TITLE OF INVENTION: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF
;   TITLE OF INVENTION: COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE
;   TITLE OF INVENTION: KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN LUNG CANCER
;   TITLE OF INVENTION: CELLS
;   FILE REFERENCE: 10001 NP
;   CURRENT APPLICATION NUMBER: US/11/169,041
;   CURRENT FILING DATE: 2005-06-28

;   PRIOR APPLICATION NUMBER: 60/584,405
;   PRIOR FILING DATE: 2004-06-30
;   NUMBER OF SEQ ID NOS: 527
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 160
;   LENGTH: 517
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-169-041-160

Query Match   28.2%; Score 257.5; DB 7; Length 517;
Best Local Similarity 36.6%; Pred. No. 4.1e-18;
Matches   64; Conservative 27; Mismatches 83; Indels   1; Gaps   1;

```
Qy      5  MFLLDSSASVSHYEFSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPPGQHSSGE   64
              ||:|:|:  |: ||:|  |:|:  :        :  :|   :::    ::   :|||
Db    143  MFLVDGSYSIGIANFVKVRAFLEVLVKSFEISPNRVQISLVQYSRDPHTEFTLKKFTKVE   202
Qy     65  AAQDAVRASAQRMGDTHTGLALVYAKEQLPAEASGARPGVPKVLVWVTDGGSSDPVGPPM   124
              |:  |:  |:|||| |: : :| :  :| ::|:  |: |:|   ::|||  ::||:
Db    203  DIIEAINTPFYRGGSTNTGKAMTYVREKIFVPSKGSRSNVPKVMILITDGKSSDAFRDPA   262
Qy    125  QELKDLGVTVFIVSTGRGNFLELSAAASAPAEKHLHFV-DVDDLHIIVQELRGSI       178
              |: : |  |   ::|:|   :::|: |:|:|       :|: : |   |||:   |
Db    263  IKLRNSDVEIFAVGVKDAVDSELEAIASPPAETHVFTVEDFDAFQRISFELTQSI       317
```

RESULT 4
US-10-131-826A-294
; Sequence 294, Application US/10131826A
; Publication No. US2005024573A1
; GENERAL INFORMATION:
;   APPLICANT: Baker, Kevin P.
;   APPLICANT: Beresini, Maureen
;   APPLICANT: DeForge, Laura
;   APPLICANT: Desnoyers, Luc
;   APPLICANT: Filvaroff, Ellen
;   APPLICANT: Gao, Wei-Qiang
;   APPLICANT: Gerritsen, Mary E.
;   APPLICANT: Goddard, Audrey
;   APPLICANT: Godowski, Paul J.
;   APPLICANT: Gurney, Austin L.
;   APPLICANT: Sherwood, Steven
;   APPLICANT: Smith, Victoria
;   APPLICANT: Stewart, Timothy A.
;   APPLICANT: Tumas, Daniel
;   APPLICANT: Watanabe, Colin K
;   APPLICANT: Wood, William
;   APPLICANT: Zhang, Zemin
;   TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;   TITLE OF INVENTION: ACIDS ENCODING THE SAME
;   FILE REFERENCE: P3330RIC128
;   CURRENT APPLICATION NUMBER: US/10/131,826A
;   CURRENT FILING DATE: 2002-04-24
;   PRIOR APPLICATION NUMBER: 60/049911
;   PRIOR FILING DATE: 1997-06-18
;   PRIOR APPLICATION NUMBER: 60/056974
;   PRIOR FILING DATE: 1997-08-26
;   PRIOR APPLICATION NUMBER: 60/059113
;   PRIOR FILING DATE: 1997-09-17
;   PRIOR APPLICATION NUMBER: 60/059115
;   PRIOR FILING DATE: 1997-09-17
;   PRIOR APPLICATION NUMBER: 60/059117
;   PRIOR FILING DATE: 1997-09-17
;   PRIOR APPLICATION NUMBER: 60/059122
;   PRIOR FILING DATE: 1997-09-17
;   PRIOR APPLICATION NUMBER: 60/059184
;   PRIOR FILING DATE: 1997-09-17
;   PRIOR APPLICATION NUMBER: 60/059263
;   PRIOR FILING DATE: 1997-09-18
;   PRIOR APPLICATION NUMBER: 60/059352
;   PRIOR FILING DATE: 1997-09-19
;   PRIOR APPLICATION NUMBER: 60/059588

```
                    GenCore version 5.1.7
          Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on:     February 13, 2006, 13:44:15 ; Search time 0.959464 Seconds
                                      (without alignments)
                              1468.904 Million cell updates/sec

Title:          US-10-699-035A-1
Perfect score:  1049
Sequence:       1 gggacctgatgtcctgct........tgaggggtccattctcgcg 537

Scoring table:  BLOSUM62
                Xgapop 10.0 , Xgapext 0.5
                Ygapop 10.0 , Ygapext 0.5
                Fgapop  6.0 , Fgapext 7.0
                Delop   6.0 , Delext  7.0

Searched:       97014 seqs, 1312538 residues

Total number of hits satisfying chosen parameters:      194028

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Command line parameters:
-MODEL=frame+_n2p.model -DEV=xlp
-Q=/abss/ABSSWEB_spool/US10699035/runat_13022006_062453_25634/app_query.fasta_1
-DB=Published_Applications_AA_New -QFMT=fastan -SUFFIX=rapbn -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100
-THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0
-MAXLEN=2000000000 -HOST=abss02p
-USER=US10699035 @CGN_1_1.10 @runat_13022006_062453_25634 -NCPU=6 -ICPU=3
-NO_MMAP -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG -DEV_TIMEOUT=120
-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6.-FGAPEXT=7
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : Published_Applications_AA_New:*
     1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
     2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
     3: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
     4: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
     5: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
     6: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
     7: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:*
     8: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	902	86.0	445	6	US-10-453-372-2	Sequence 2, Appli
2	261.5	24.9	3063	7	US-11-186-284-26	Sequence 26, Appl
3	257.5	24.5	517	7	US-11-169-041-160	Sequence 160, App
4	246.5	23.5	915	6	US-10-131-826A-294	Sequence 294, App
5	246.5	23.5	956	7	US-11-113-424-39	Sequence 39, Appl
6	197	18.8	214	7	US-11-192-449-6	Sequence 6, Appli
7	197	18.8	214	7	US-11-192-449-9	Sequence 9, Appli
8	188	17.9	214	7	US-11-192-449-5	Sequence 5, Appli
9	183	17.4	678	6	US-10-063-703-34	Sequence 34, Appl
10	183	17.4	678	7	US-11-102-240-34	Sequence 34, Appl
11	166.5	15.9	1152	7	US-11-080-026-4	Sequence 4, Appli
12	162	15.4	709	6	US-10-453-372-186	Sequence 186, App
13	161	15.3	709	6	US-10-453-372-180	Sequence 180, App
14	161	15.3	3568	6	US-10-453-372-194	Sequence 194, App
15	161	15.3	3570	6	US-10-453-372-178	Sequence 178, App
16	161	15.3	3570	6	US-10-453-372-196	Sequence 196, App
17	161	15.3	3570	6	US-10-453-372-198	Sequence 198, App
18	161	15.3	3570	6	US-10-453-372-200	Sequence 200, App
19	161	15.3	3570	6	US-10-453-372-202	Sequence 202, App
20	161	15.3	3570	6	US-10-453-372-204	Sequence 204, App
21	161	15.3	709	6	US-10-453-372-206	Sequence 206, App
22	160	15.3	709	6	US-10-453-372-182	Sequence 182, App
23	155	14.8	1167	6	US-10-453-372-184	Sequence 184, App
24	150.5	14.3	1141	6	US-10-601-368-18	Sequence 18, Appl
25	150	14.3	1166	6	US-10-601-368-24	Sequence 24, Appl
26	150	14.3	1188	6	US-10-601-368-22	Sequence 22, Appl
27	150	14.3	182	6	US-10-601-368-21	Sequence 21, Appl
28	149.5	13.9	1147	6	US-10-601-368-25	Sequence 25, Appl
29	145.5	13.8	1141	6	US-10-453-372-4	Sequence 4, Appli
30	145	13.8	1166	6	US-10-601-368-6	Sequence 6, Appli
31	145	13.8	1188	6	US-10-601-368-4	Sequence 4, Appli
32	145	13.8	1188	6	US-10-601-368-3	Sequence 3, Appli
33	145	13.8	1188	7	US-11-000-463-338	Sequence 338, App
34	145	13.8	182	7	US-11-000-463-810	Sequence 810, App
35	144.5	13.8	2764	6	US-10-601-368-7	Sequence 7, Appli
36	144.5	13.8	2813	6	US-10-995-561-691	Sequence 691, App
37	144.5	13.8	2919	6	US-10-995-561-688	Sequence 688, App
38	134.5	12.8	1179	6	US-10-821-234-1133	Sequence 1133, Ap
39	134.5	12.8	1196	7	US-11-097-125-1	Sequence 1, Appli
40	134	12.8	184	6	US-10-995-561-921	Sequence 921, App
41	133	12.7	184	6	US-10-665-658-8	Sequence 8, Appli
42	133	12.7	1170	6	US-10-665-658-7	Sequence 7, Appli
43	133	12.7	1170	7	US-11-080-026-2	Sequence 2, Appli
44	128	12.2	1167	7	US-11-107-028-4	Sequence 4, Appli
45	128	12.2	1167	7	US-11-097-125-2	Sequence 2, Appli

ALIGNMENTS

```
RESULT 1
US-10-453-372-2
; Sequence 2, Application US/10453372
; Publication No. US20060003323A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METI
; FILE REFERENCE: 21402-589 A
; CURRENT APPLICATION NUMBER: US/10/453,372
; CURRENT FILING DATE: 2003-06-03
; PRIOR APPLICATION NUMBER: 09/789390
; PRIOR FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: 60/185967
; PRIOR FILING DATE: 2000-03-01
; PRIOR APPLICATION NUMBER: 09/823187
; PRIOR FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: 60/195792
; PRIOR FILING DATE: 2000-03-10
; PRIOR APPLICATION NUMBER: 60/839446
; PRIOR FILING DATE: 2001-03-19
; PRIOR APPLICATION NUMBER: 60/199476
; PRIOR FILING DATE: 2000-03-25
; PRIOR APPLICATION NUMBER: 09/863776
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/208263
; PRIOR FILING DATE: 2000-05-31
; PRIOR APPLICATION NUMBER: 09/939398
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: 60/227800
; PRIOR FILING DATE: 2000-08-25
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1609
; SOFTWARE: CuraSeqList version 0.1
```

ion Feb 13 15:15:02 2006

SEQ ID NO 2
LENGTH: 445
TYPE: PRT
ORGANISM: Homo sapiens
-10-453-372-2

ignment Scores:	
ed. No.:	Length: 445
ore: 1.63e-62	Matches: 178
rcent Similarity: 902.00	Conservative: 0
st Local Similarity: 100.0%	Mismatches: 0
ery Match: 100.0%	Indels: 0
: 86.0%	Gaps: 0

s-10-699-035a-1 (1-537) x US-10-453-372-2 (1-445)

```
y    1 GGGGACCTGATGTTCCTGCTGGACAGCTCAGCCAGCGTCTTCCACTACGAGTTCTCCGG  60
b                                                                   
b   33 GlyAspLeuMetPheLeuLeuAspSerSerAlaSerValSerHisTyrrGluPheSerArg  52

y   61 GTTCGGGAGTTTGTGGGGCAGCTGGTGGCTCCACTGCCCCTGGGCACCGGGGCCCTGCGT 120
y   53 ValArgGluPheValGlyGlnLeuValAlaProLeuProLeuGlyThrGlyAlaLeuArg  72

b  121 GCCAGTCTCGTGCACGTGGGCAGTCGGCCATACACCGGAGTTCCCCTTCGGCCAGCACAGC 180
y   73 AlaSerLeuValHisValGlySerArgProTyrThrGluPheProPheGlyGlnHisSer  92

y  181 TCGGGTGAGGCTGCCCAGGATGCGGTGCGCTTCTGCCCAGCGCCATGGGTGACACCCAC  240
y   93 SerGlyGluAlaAlaGlnAspAlaValArgAlaSerAlaGlnArgMetGlyAspThrHis 112

y  241 ACTGGGCCTGGCCGCTGGTCTATGCCCAAGGAACAGCTGTTTGCTGAAGCATCAGGTGCC 300
b  113 SerGlyGluAlaAlaGlnAspAlaValArgAlaSerAlaGlnArgMetGlyAspThrHis 132

Qy 241 ACTGGGCCTGGCCGCTGGTCTATGCCCAAGGAACAGCTGTTTGCTGAAGCATCAGGTGCC 243
Db 113 ThrGlyLeuAlaLeuValTyrAlaLysGluGlnLeuPheAlaGluAlaSerGlyAlaArg 132

Qy 301 CCAGGGGGTGCCCAAAGTGCTGGTGTGGGTGACAGATGGCGGCTCCAGCGACCCTGTGGGC 360
Db 133 ProGlyValProLysValLeuValTrpValThrAspGlyGlySerSerAspProValGly 152

Qy 361 CCCCCCATGCCAGGAGCTCAAGGACCTGGGCGTCAGGTGTTCATTGTCAGCGAGAAGCACC 420
Db 153 ProProMetProGlyAlaGlnGlyLeuGlyValGlnValPheIleValSerGluLysHis 172

Db 421 GGCAACTTCCTGGAGCTGTCCAGCCCGTGCCTCAGCCCGTCCGAGAAGACCTGCACTTT 480
Qy 173 GlyAsnPheLeuGluLeuSerSerProCysLeuSerProSerGluLysThrCysThrPhe 192

Db 481 GTGGGACGTGGATGACCTGCACATCATTGTCCAAGAGCTGAGAGGGGCTCCATT 534
Qy 193 ValAspValAspAspLeuHisIleIleValGlnGluLeuArgGlyAlaPro 210
```

PRIOR APPLICATION NUMBER: US 60/339,971
PRIOR FILING DATE: 2001-12-10
PRIOR APPLICATION NUMBER: US 60/361,978
PRIOR FILING DATE: 2002-03-05
PRIOR APPLICATION NUMBER: US 60/381,988
PRIOR FILING DATE: 2002-05-20
NUMBER OF SEQ ID NOS: 228
SOFTWARE: PatSEQ for Windows Version 4.0

SEQ ID NO 26
LENGTH: 3063
TYPE: PRT
ORGANISM: Homo sapiens
US-11-186-284-26

Alignment Scores:	
Pred. No.:	Length: 3063
Score: 261.50	Matches: 64
Percent Similarity: 52.5%	Conservative: 29
Best Local Similarity: 36.2%	Mismatches: 83
Query Match: 24.9%	Indels: 1
DB: 2.2e-13	Gaps: 1

US-10-699-035A-1 (1-537) x US-11-186-284-26 (1-3063)

```
Qy   4 GACCTGATGTTCCTGCTGGACAGCTCAGCCAGCGTCTCTCACTACGAGTTCTCCGGGGT  63
Db 440 AspIleValPheLeuValAspGlySerTyrSerIleGlyIleAlaAsnPheValLysVal 459

Qy  64 CGGGAGTTTGTGGGGCAGCTGGTGGCTCCACTGCCCCTGGGCACCGGGGCCCTGCGTGCC 123
Db 460 ArgAlaPheLeuGluValLeuValLysSerProAsnArgValGlnIle              479

Qy 124 AGTCTCGTGCACGTGGGCAGTCGGCCATACACCGGAGTTCCCCTTCGGCCAGCACAGCTCG 183
Db 480 SerLeuValGlnTyrSerArgArgAspProHisThrGluPheProPheArgGlnHisThrThrLeuLysPheThrLys 499

Qy 184 GGTGAGGCTGCCCAGGATGCGGTGCGCTTCTGCCCAGCGCCATGGGTGACACCCACACT 243
Db 500 ValGluAspIleIleGluIleAlaGluAsnThrPheProTyrArgGlyGlySerThrAsnThr 519

Db 244 GGGCCTGGCCGCTGGTCTATGCCCAAGGAACAGCTGTTTGCTGAAGCATCAGGTGCCCCAGGGCCA 303
Qy 500 ValGluAspIleIleGluIleAlaGluAsnThrPheProTyrArgGlyGlySerThrAsnThr 539

Db 304 GGGGTGCCCAAAGTGCTGGTGTGGGTGACAGATGGCGGCTCCAGCGACCCTGTGGGCCCC 363
Qy 520 GlyLysAlaMetThrTyrValArgValLysIlePheValProSerLysGlySerArgSer 539

Db 364 CCCATGCCAGGAGCTCAAGGACCTGGGCGTCAGGTGTTCATTGTCAGCGAGAAGCACGGC 423
Qy 540 AsnValProLysValMetIleLeuIleLeuThrAspGlyLysSerSerAspAlaPheArgAspAsp 559

Db 424 AACTTCCTGGAGCTGTCCAGCCCGTGCCTCAGCCCGTCCGAGAAGACCTGCACTTTGTG 483
Qy 560 ProAlaIleLysLeuArgAsnSerAspValGluIlePheAlaValGlyValLysAspAla 579

Db 484 ---GACGTGGATGACCTGCACATCATTGTCCAAGAGCTGAGAGGGGCTCCATT        531
Qy 580 ValArgSerGluLeuGluGluIleAlaIleGluAlaSerProProAlaGluThrHisValPheThrVal 599

Qy 600 GluAspPheAspAlaPheGlnAsnArgIleSerPheGluLeuThrGlnSerIle        616
```

RESULT 2
US-11-186-284-26
; Sequence 26, Application US/11186284
; Publication No. US2005026493A1
; GENERAL INFORMATION:
; APPLICANT: Millennium Pharmaceuticals, Inc.
; APPLICANT: Berger, Allison
; APPLICANT: Guillemette, Tracy L.
; APPLICANT: Kamatkar, Shubhangi
; APPLICANT: Schlegel, Robert
; APPLICANT: Monahan, John B.
; APPLICANT: Thibodeau, Stephen N.
; APPLICANT: Burgart, Lawrence J.
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND
; TITLE OF INVENTION: METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND
; TITLE OF INVENTION: THERAPY OF COLON CANCER
; FILE REFERENCE: MPM01-029P2RNM
; CURRENT APPLICATION NUMBER: US/11/186,284
; CURRENT FILING DATE: 2005-07-21
; PRIOR APPLICATION NUMBER: US/10/301,822
; PRIOR FILING DATE: 2002-11-21

RESULT 3
US-11-169-041-160
; Sequence 160, Application US/11169041
; Publication No. US2006001928A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF
; TITLE OF INVENTION: COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE
; TITLE OF INVENTION: KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN LUNG CANCER
; TITLE OF INVENTION: CELLS
; FILE REFERENCE: 10001 NP
; CURRENT APPLICATION NUMBER: US/11/169,041
; CURRENT FILING DATE: 2005-06-28

OM nucleic - protein search, using frame_plus_n2p model

```
                GenCore version 5.1.7
       Copyright (c) 1993 - 2006 Biocceleration Ltd.
```

Run on: February 13, 2006, 13:44:15 ; Search time 2.24054 Seconds
                                          (without alignments)
                                        1468.904 Million cell updates/sec

Title: US-10-699-035A-5
Perfect score: 2380
Sequence: 1 atgtcccctggacggcgct.........cgcagccgtgagccgtaa 1254

Scoring table: BLOSUM62
              Xgapop 10.0 , Xgapext 0.5
              Ygapop 10.0 , Ygapext 0.5
              Fgapop 6.0 , Fgapext 7.0
              Delop   6.0 , Delext   7.0

Searched: 97014 seqs, 13122538 residues

Total number of hits satisfying chosen parameters: 194028

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Command line parameters:
-MODEL=frame+ n2p.model -DEV=xlp
-Q=/abss/ABSSWEB_spool/US10699035/runat_13022006_062453_25634/app_query.fasta_1
-DB=Published Applications AA_New -QMT=fastan -SUFFIX=rapbn -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100
-THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0
-MAXLEN=2000000000 -HOST=abss02p
-USER=US10699035 @CGN_1_1_10 @runat_13022006_062453_25634 -NCPU=6 -ICPU=3
-NO_MMAP -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG -DEV TIMEOUT=120
-WARN TIMEOUT=30 -THREADS=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6 -FGAPEXT=7
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :   Published Applications_AA_New.*
          1: /cgn2_6/ptcodata/2/pubpaa/US08_NEW_PUB.pep.*
          2: /cgn2_6/ptcodata/2/pubpaa/US06_NEW_PUB.pep.*
          3: /cgn2_6/ptcodata/2/pubpaa/US07_NEW_PUB.pep.*
          4: /cgn2_6/ptcodata/2/pubpaa/US_PCT_NEW_PUB.pep.*
          5: /cgn2_6/ptcodata/2/pubpaa/US09_NEW_PUB.pep.*
          6: /cgn2_6/ptcodata/2/pubpaa/US10_NEW_PUB.pep.*
          7: /cgn2_6/ptcodata/2/pubpaa/US11_NEW_PUB.pep.*
          8: /cgn2_6/ptcodata/2/pubpaa/US60_NEW_PUB.pep.*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Match | Query Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 2114 | 88.8 | 445 | 6 | US-10-453-372-2 | Sequence 2, Appli |
| 2 | 419 | 17.6 | 3063 | 7 | US-11-186-284-26 | Sequence 26, App |
| 3 | 398.5 | 16.7 | 517 | 7 | US-11-169-041-160 | Sequence 160, App |
| c 4 | 254.5 | 10.7 | 1717 | 7 | US-11-182-016-20 | Sequence 20, Appl |
| 5 | 253.5 | 10.7 | 915 | 6 | US-10-131-826A-294 | Sequence 294, App |
| 6 | 253.5 | 10.7 | 956 | 7 | US-11-113-424-39 | Sequence 39, Appl |
| 7 | 221.5 | 9.3 | 1366 | 6 | US-10-821-234-1431 | Sequence 1431, Ap |
| 8 | 221.5 | 9.3 | 1366 | 7 | US-11-186-284-31 | Sequence 31, Appl |
| 9 | 215 | 9.0 | 1496 | 7 | US-11-186-284-35 | Sequence 35, Appl |
| 10 | 212 | 8.9 | 1464 | 7 | US-11-000-463-243 | Sequence 243, App |
| 11 | 212 | 8.9 | 1464 | 7 | US-11-186-284-28 | Sequence 28, Appli |
| 12 | 212 | 8.9 | 1464 | 7 | US-11-021-603-2 | Sequence 2, Appli |
| 13 | 212 | 8.9 | 1467 | 6 | US-10-821-234-1096 | Sequence 1096, Ap |
| c 14 | 211 | 8.9 | 1464 | 7 | US-11-000-463-243 | Sequence 243, App |
| c 15 | 211 | 8.9 | 1464 | 7 | US-11-186-284-28 | Sequence 28, Appl |
| c 16 | 211 | 8.9 | 1464 | 7 | US-11-021-603-2 | Sequence 2, Appli |
| 17 | 211 | 8.8 | 1467 | 6 | US-10-821-234-1096 | Sequence 1096, Ap |
| 18 | 210.5 | 8.8 | 1166 | 6 | US-10-821-234-964 | Sequence 964, App |
| 19 | 210.5 | 8.8 | 1466 | 7 | US-11-186-284-33 | Sequence 33, Appl |
| c 20 | 206.5 | 8.7 | 1733 | 6 | US-11-182-016-21 | Sequence 21, Appl |
| c 21 | 203.5 | 8.6 | 1466 | 7 | US-11-186-284-33 | Sequence 33, Appl |
| 22 | 202 | 8.5 | 1733 | 7 | US-11-182-016-21 | Sequence 21, Appl |
| c 23 | 200.5 | 8.4 | 1823 | 6 | US-10-995-561-988 | Sequence 988, App |
| c 24 | 200.5 | 8.4 | 2102 | 6 | US-10-995-561-990 | Sequence 990, App |
| c 25 | 200.5 | 8.4 | 2108 | 6 | US-10-995-561-989 | Sequence 989, App |
| 26 | 200.5 | 8.4 | 2157 | 6 | US-10-995-561-991 | Sequence 991, App |
| 27 | 199 | 8.4 | 214 | 7 | US-11-192-449-6 | Sequence 6, Appli |
| 28 | 199 | 8.4 | 214 | 7 | US-11-192-449-9 | Sequence 9, Appli |
| 29 | 199 | 8.4 | 1717 | 7 | US-11-182-016-20 | Sequence 20, Appl |
| c 30 | 198.5 | 8.3 | 1366 | 6 | US-10-821-234-1431 | Sequence 1431, Ap |
| c 31 | 198.5 | 8.3 | 1366 | 7 | US-11-186-284-31 | Sequence 31, Appl |
| c 32 | 198.5 | 8.3 | 1742 | 7 | US-11-182-016-23 | Sequence 23, Appl |
| 33 | 197 | 8.3 | 843 | 7 | US-11-129-104-89 | Sequence 89, Appl |
| 34 | 196.5 | 8.3 | 3570 | 6 | US-10-453-372-196 | Sequence 196, App |
| 35 | 195.5 | 8.2 | 3570 | 6 | US-10-453-372-178 | Sequence 178, App |
| 36 | 195.5 | 8.2 | 3570 | 6 | US-10-453-372-198 | Sequence 198, App |
| 37 | 195.5 | 8.2 | 3570 | 6 | US-10-453-372-200 | Sequence 200, App |
| 38 | 195.5 | 8.2 | 3570 | 6 | US-10-453-372-202 | Sequence 202, App |
| 39 | 195.5 | 8.2 | 3570 | 6 | US-10-453-372-204 | Sequence 204, App |
| 40 | 195.5 | 8.2 | 3570 | 6 | US-10-453-372-206 | Sequence 206, App |
| 41 | 192.5 | 8.1 | 1251 | 6 | US-11-149-003-16 | Sequence 16, Appl |
| 42 | 192 | 8.1 | 709 | 6 | US-10-453-372-182 | Sequence 182, App |
| c 43 | 191 | 8.0 | 495 | 7 | US-11-182-016-31 | Sequence 31, Appl |
| 44 | 190.5 | 8.0 | 709 | 6 | US-10-453-372-180 | Sequence 180, App |
| 45 | 190.5 | 8.0 | 709 | 6 | US-10-453-372-186 | Sequence 186, App |

ALIGNMENTS

RESULT 1
US-10-453-372-2
; Sequence 2; Application US/10/453,372
; Publication No. US20060003323A1
; GENERAL INFORMATION:
;   APPLICANT: Alsobrook, et al.
;   TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METH(
;   FILE REFERENCE: 21402-589 A
;   CURRENT APPLICATION NUMBER: US/10/453,372
;   CURRENT FILING DATE: 2003-06-03
;   PRIOR APPLICATION NUMBER: 09/789390
;   PRIOR FILING DATE: 2001-02-23
;   PRIOR APPLICATION NUMBER: 60/185967
;   PRIOR FILING DATE: 2000-03-01
;   PRIOR APPLICATION NUMBER: 09/823187
;   PRIOR FILING DATE: 2001-03-29
;   PRIOR APPLICATION NUMBER: 60/195792
;   PRIOR FILING DATE: 2000-03-10
;   PRIOR APPLICATION NUMBER: 09/839446
;   PRIOR FILING DATE: 2001-03-19
;   PRIOR APPLICATION NUMBER: 60/199476
;   PRIOR FILING DATE: 2000-03-25
;   PRIOR APPLICATION NUMBER: 09/863776
;   PRIOR FILING DATE: 2001-05-23
;   PRIOR APPLICATION NUMBER: 60/208263
;   PRIOR FILING DATE: 2000-05-31
;   PRIOR APPLICATION NUMBER: 09/939398
;   PRIOR FILING DATE: 2001-08-24
;   PRIOR APPLICATION NUMBER: 60/227800
;   PRIOR FILING DATE: 2000-08-25
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1609
; SOFTWARE: CuraSeqlist version 0.1

; SEQ ID NO 2
; LENGTH: 445
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-453-372-2

Alignment Scores:
Pred. No.:          2.77e-113
Score:              2114.00
Percent Similarity: 93.7%
Best Local Similarity: 93.7%
Query Match:        88.8%
DB:                 6

Length:       445
Matches:      417
Conservative: 0
Mismatches:   0
Indels:       28
Gaps:         2

US-10-699-035A-5 (1-1254) x US-10-453-372-2 (1-445)

```
Qy    1 ATGCTCCCTGACGGCGCTGGCCCTGAGCCTGCGCCTGGCGCTGGCGCGGAGC  60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1 MetLeuProTrpThrAlaLeuGlyLeuAlaLeuSerLeuArgLeuAlaLeuAlaArgSer  20

Qy   61 GGGCGGCGGAGCGGCGGTCCACCAGCATCAGCCCCCGAGGGGACCTGATGTTCCTGCTGAC  120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   21 GlyAlaGluArgGlyProProAlaSerAlaProAlaProAlaProGlyAspLeuMetPheLeuLeuAsp  40

Qy  121 AGCTCAGCCAGCGTCTCACTACGAGTTCTCCCGGGTTCGGGAGTTTGTGGGGCAGCTG  180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   41 SerSerAlaSerValSerHisTyrGluPheSerArgValArgGluPheValGlyGlnLeu  60

Qy  181 GTGGCTCCACTGCCCCTGGGACCGGGACCGCTGCCAGTCTCGTGCACGTGGGCAGT  240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 ValAlaProLeuProLeuGlyThrGlyThrGlyAlaLeuArgLeuArgLeuAlaSerLeuValHisValGlySer  80

Qy  241 CGGCCATACACCGAGTTCCCCTTGCGCCAGCAGCTCGGGTGAGGCTGCCAGATGCG  300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   81 ArgProTyrThrGluPheProPheGlyGlnHisSerSerGlyGluAlaAlaGlnAsnAspAla  100

Qy  301 GTGCGTGCTTCTGCCCAGCGCATGGTGACACCCACACTGGCCTGGCCTGGTCTATGCC  360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  101 ValArgAlaSerArgAlaGlnArgMetGlyAspThrHisThrGlyLeuAlaLeuValTyrAla  120

Qy  361 AAGGAACAGCTGTTTGCTGAAGCATCAGTGCCCGGCCAGGGGTGCCAAAGTGCTGGTG  420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 LysGluGlnLeuPheAlaGluAlaSerGlyAlaArgProGlyValProLysValLeuVal  140

Qy  421 TGGGTGACAGATGGCGGCTCCAGCGACCCTGTGGCCCCCATGCAGGAGCTCAAGGAC  480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  141 TrpValThrAspGlyGlySerSerAspProValGlyProProMetGlnGluLeuLysAsp  160

Qy  481 CTGGGGCGTCACCGTGTTCATTGTCAGCACCGACCGGCCAGCAACTTCCTGGAGCTGTCAGCC  540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  161 LeuGlyValThrValPheIleValSerThrGlyArgGlyValGlyAsnPheLeuGluLeuSerAla  180

Qy  541 GCTGCCTCAGCCCCTGCCGAGAGCACCTGCACTTGTGGACGTGGATGACTGCACATC  600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  181 AlaAlaSerAlaProAlaGluSerHisLeuHisLeuTrpThrValAspValAspAspLeuHisIle  200

Qy  601 ATTGTCCAAGAGCTGAGGGGCTCCATTCTC---GCGATGCGGCCGCAGCAGCTCCATGCC  657
          |||||||||||||||||||||||||     ||||||||||||||||||||||
Db  201 IleValGlnGluLeuArgGlySerIleLeuLeuAlaMetArgProGlnGlnLeuHisAla  220

Qy  658 ACGGAGATCACGTCAGCGGCTTCCAGCGGCTTCCGCCTGGCCACCCCTGTCTGACCGCAGACTCG  717
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  221 ThrGluIleThrSerSerGlyPheArgLeuAlaThrProProLeuThrAlaAspSer  240

Qy  718 GGCTACTATGTGCTGGAGCTGTGTCCCAGCGCCCAGCGCGGGGGCTGCAAGAGCGCCAGCAG  777
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  241 GlyTyrTyrValLeuGluLeuCysProSerAlaGlnArgGlyGlyCysLysArgAlaArgGlnGln  260

Qy  778 CTGCCAGGGAACGCCACGGACTGGATCTGGGCGGCCTGAACACCCGACACGGACTACGAC  837
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  261 LeuProGlyAsnAlaThrAspTrpIleTrpAlaGlyLeuAsnProArgHisGlyTyrAsp  280

Qy  838 GTGGCGCTAGTGCCTGCCAGTCCAACGTGCCGCCTCGTGAGGCCCGAGATCCTGCGGGTGCGC  897
```

```
Db  281 ValAlaLeuValProGluSerAsnValAlaArgLeuLeuLeuArgProGlnIleLeuLeuArgValArg  300

Qy  898 ACGCGG------------------------------  903
          ||||||
Db  301 ThrArgProGlyValAlaGlyProGluSerGlyAlaGlyProAla  320

Qy  904 ---------------------CCAGAGGAGGCCGGGCCAGAGCGCATCGTCATC  936
                              ||||||||||||||||||||||||
Db  321 ProThrGlnLeuAlaAlaLeuProAlaProGluGluProGluGluArgIleValIle  340

Qy  937 TCCCACGCCGCCGGCCCAGCCTCCGGCTGAGTGGGCCCCAGCGTCTGGGCTCAGCCGCCG  996
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  341 SerHisAlaArgProArgSerLeuArgValSerTrpProAlaProAlaLeuGlySerAlaAla  360

Qy  997 GCGCTCGGCTACCACGTGCAGTTCGGCGCCGTCGGCGGCGGCGGGGAGGGGCGGTGGAG  1056
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  361 AlaLeuGlyTyrHisValGlnPheGlyAlaValGlyLeuProLeuArgGlyGlnArgValGlu  380

Qy  1057 GTGCCCGGCGGCGCCAACTGCCACCACGCTGCAGGGCCTGGCGGCCACCGCCTACCTG  1116
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  381 ValProAlaGlyAlaAsnCysThrThrLeuGlnGlyLeuLeuAlaProGlyThrAlaTyrLeu  400

Qy  1117 GTGACCGTGACCGGCCGCCTTCCGCTCGGGCCGGAGAGCCGCTGTCCGGCCAAGGGCCTGC  1176
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  401 ValThrValThrAlaAlaPheArgSerGlyArgGluSerArgAlaLeuSerArgAlaLysAla Cys  420

Qy  1177 ACGCCCGACGCCCGGCCCGCCCGCCCCGTGCCCCCGACCCCGGGACC  1236
          ||||||||||||||||||||||||||||||||||||||||||||||
Db  421 ThrProAspGlyProArgProArgProArgProAlaProThrProGlyThr  440

Qy  1237 GCCAGCCGGTGAGCCG  1251
          ||||||
Db  441 AlaSerArgGluPro  445
```

RESULT 2
US-11-186-284-26
; Sequence 26, Application US/1118624
; Publication No. US20050266493A1
; GENERAL INFORMATION:
; APPLICANT: Millennium Pharmaceuticals, Inc.
; APPLICANT: Berger, Allison
; APPLICANT: Guillemette, Tracy L.
; APPLICANT: Kamatkar, Shubhangi
; APPLICANT: Schlegel, Robert
; APPLICANT: Monahan, John E.
; APPLICANT: Thibodeau, Stephen N.
; APPLICANT: Burgart, Lawrence J.
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND
; TITLE OF INVENTION: METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND
; TITLE OF INVENTION: THERAPY OF COLON CANCER
; FILE REFERENCE: MPM01-029P2RNM
; CURRENT APPLICATION NUMBER: US/11/186,284
; CURRENT FILING DATE: 2005-07-21
; PRIOR APPLICATION NUMBER: US/10/301,822
; PRIOR FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: US 60/339,971
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: US 60/361,978
; PRIOR FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: US 60/381,988
; PRIOR FILING DATE: 2002-05-20
; NUMBER OF SEQ ID NOS: 228
; SOFTWARE: PatentIn for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 3063
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-11-186-284-26

Alignment Scores:
Pred. No.:   1.5e-17
Score: 419.00

Length: 3063
Matches: 128